WO2021254449A1 - 一种shp2抑制剂的晶型及其组合物、制备方法和用途 - Google Patents
一种shp2抑制剂的晶型及其组合物、制备方法和用途 Download PDFInfo
- Publication number
- WO2021254449A1 WO2021254449A1 PCT/CN2021/100673 CN2021100673W WO2021254449A1 WO 2021254449 A1 WO2021254449 A1 WO 2021254449A1 CN 2021100673 W CN2021100673 W CN 2021100673W WO 2021254449 A1 WO2021254449 A1 WO 2021254449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- compound
- diffraction pattern
- ray powder
- powder diffraction
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 239000003112 inhibitor Substances 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 19
- 229940125904 compound 1 Drugs 0.000 claims abstract description 225
- 239000012453 solvate Substances 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
- 239000013078 crystal Substances 0.000 claims description 603
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 424
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 118
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 82
- 238000001228 spectrum Methods 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 27
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 3
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010073360 Appendix cancer Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010029748 Noonan syndrome Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 2
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 241000282373 Panthera pardus Species 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 208000033014 Plasma cell tumor Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 2
- 208000021388 Sezary disease Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 2
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 208000025188 carcinoma of pharynx Diseases 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000002529 islet cell tumor Diseases 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000036244 malformation Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 208000021284 ovarian germ cell tumor Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 201000003913 parathyroid carcinoma Diseases 0.000 claims description 2
- 208000017954 parathyroid gland carcinoma Diseases 0.000 claims description 2
- 208000010916 pituitary tumor Diseases 0.000 claims description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000003981 ectoderm Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 201000000284 histiocytoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 208000029211 papillomatosis Diseases 0.000 claims 1
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- PQNDHWFSXFZDJE-LJQANCHMSA-N (5S)-1'-[8-(2-amino-3-chloropyridin-4-yl)sulfanylimidazo[1,2-c]pyrimidin-5-yl]spiro[5,7-dihydrocyclopenta[b]pyridine-6,4'-piperidine]-5-amine Chemical compound NC1=NC=CC(=C1Cl)SC=1C=2N(C(=NC=1)N1CCC3(CC1)[C@@H](C=1C(=NC=CC=1)C3)N)C=CN=2 PQNDHWFSXFZDJE-LJQANCHMSA-N 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 102
- 238000002411 thermogravimetry Methods 0.000 description 64
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- 238000004128 high performance liquid chromatography Methods 0.000 description 58
- 239000007787 solid Substances 0.000 description 57
- 239000002904 solvent Substances 0.000 description 57
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- 238000012360 testing method Methods 0.000 description 39
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- 239000012535 impurity Substances 0.000 description 32
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 32
- -1 1-methylpentyl Chemical group 0.000 description 27
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000012296 anti-solvent Substances 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 24
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 18
- 230000004580 weight loss Effects 0.000 description 18
- 239000012046 mixed solvent Substances 0.000 description 17
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 15
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 238000011835 investigation Methods 0.000 description 13
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 150000001298 alcohols Chemical class 0.000 description 11
- 229940011051 isopropyl acetate Drugs 0.000 description 11
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 11
- 239000004810 polytetrafluoroethylene Substances 0.000 description 11
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 10
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 10
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 9
- 150000001335 aliphatic alkanes Chemical class 0.000 description 9
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 8
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 150000002170 ethers Chemical class 0.000 description 8
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- 238000010009 beating Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 150000008282 halocarbons Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010183 spectrum analysis Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000001273 butane Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000001294 propane Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000002076 thermal analysis method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 244000291414 Vaccinium oxycoccus Species 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- AUILZYBLVOCLDX-UHFFFAOYSA-N 1-methylpyrrolidin-2-one;toluene Chemical compound CN1CCCC1=O.CC1=CC=CC=C1 AUILZYBLVOCLDX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 102100037709 Desmocollin-3 Human genes 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 1
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000001715 Osteoblastoma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 101710204864 Tyrosine-protein phosphatase 2 Proteins 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
- IKWTVSLWAPBBKU-UHFFFAOYSA-N a1010_sial Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007805 chemical reaction reactant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- YEMWINDXAKRPBK-UHFFFAOYSA-N heptane;2-methoxy-2-methylpropane Chemical compound COC(C)(C)C.CCCCCCC YEMWINDXAKRPBK-UHFFFAOYSA-N 0.000 description 1
- JYGYEBCBALMPDC-UHFFFAOYSA-N heptane;propan-2-one Chemical compound CC(C)=O.CCCCCCC JYGYEBCBALMPDC-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- This application provides (S)-1'-(8-((2-amino-3-chloropyridin-4-yl)thio)imidazo[1,2-c]pyrimidin-5-yl)-5, New crystal forms of 7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine, hydrates and solvates thereof, and pharmaceutical compositions containing the new crystal forms .
- This application also discloses the preparation method and application of the novel crystal form.
- SHP2 protein tyrosine phosphatase-2 containing SH2 domain
- SHP2 occupies an extremely important position in the process of cell signal transduction, and is a target for the development of treatment of major diseases such as diabetes, autoimmune diseases and cancer.
- the compound may exist in one or more crystalline forms, and the crystalline forms used as pharmaceutical active ingredients may have different chemical and physical properties, such as melting point, solubility, dissolution rate, hygroscopicity, density, fluidity, stability and bioavailability These properties have a direct impact on the processing and/or manufacturing capabilities of the compound as a pharmaceutical product.
- the difference in crystallization conditions and storage conditions may lead to changes in the crystal structure of the compound, sometimes accompanied by the production of other crystalline forms.
- this application provides multiple novel crystal forms of Compound 1, its hydrates and solvates.
- this application provides the crystalline form A of compound 1, characterized in that the X-ray powder diffraction pattern of the crystalline form A has one or more peaks selected from the following group: about 6.46°, about 12.64° and approximately 12.93° 2 ⁇ .
- the present application provides the crystalline form B of the hydrate of compound 1, characterized in that the X-ray powder diffraction pattern of the crystalline form B has one or more peaks selected from the following group: about 7.36 °, about 10.82° and about 11.10°2 ⁇ .
- this application provides the crystalline form C of the hydrate of compound 1, characterized in that the X-ray powder diffraction pattern of the crystalline form C has one or more peaks selected from the following group: about 7.33 °, about 11.08° and about 14.70°2 ⁇ .
- the present application provides the crystalline form D of the dichloromethane solvate of compound 1, characterized in that the X-ray powder diffraction pattern of the crystalline form D has one or more peaks selected from the following group : About 8.24°, about 13.46° and about 15.32° 2 ⁇ .
- this application provides the crystalline form E of the isopropanol solvate of compound 1, characterized in that the X-ray powder diffraction pattern of the crystalline form E has one or more peaks selected from the following group : About 9.10°, about 13.49° and about 18.24°2 ⁇ .
- the present application provides a pharmaceutical composition comprising a novel crystal form of Compound 1.
- the present application provides a novel crystal form of Compound 1 and a method for preparing a pharmaceutical composition containing the novel crystal form.
- the present application provides a novel crystal form of Compound 1 and the use of a pharmaceutical composition comprising the novel crystal form.
- Figure 1 shows the X-ray powder diffraction (XRPD) pattern of the crystal form A of compound 1.
- Figure 2 shows the differential scanning calorimetry/thermogravimetric analysis (DSC/TGA) spectrum of the crystalline form A of compound 1.
- Figure 3 shows the XRPD pattern of the crystalline form B of the hydrate of compound 1.
- Figure 4 shows the DSC/TGA chart of the crystalline form B of the hydrate of compound 1.
- Figure 5 shows the XRPD pattern of Form C of the hydrate of Compound 1.
- Figure 6 shows the DSC/TGA spectrum of the crystalline form C of the hydrate of compound 1.
- Figure 7 shows the XRPD pattern of Form D of the dichloromethane solvate of Compound 1.
- Figure 8 shows the DSC/TGA pattern of the crystalline form D of the dichloromethane solvate of Compound 1.
- Figure 9 shows the XRPD pattern of Form E of the isopropanol solvate of Compound 1.
- Figure 10 shows the DSC/TGA pattern of Form E of the isopropanol solvate of Compound 1.
- Figures 11A to 11E show the crystal form A of compound 1 under three stability test conditions (25°C/60%RH/1 week, 40°C/75%RH/1 week and 60°C/closed/24 hours) High performance liquid chromatography (HPLC) profile.
- HPLC High performance liquid chromatography
- Figure 12 shows the XRPD patterns of the crystal form A of compound 1 under three stability test conditions (25°C/60%RH/1 week, 40°C/75%RH/1 week and 60°C/closed/24 hours) .
- Fig. 13 shows the dynamic vapor adsorption (DVS) test spectrum of the crystal form A of compound 1 in the hygroscopicity investigation test of the crystal form A of compound 1.
- Figure 14 shows the comparison of XRPD patterns of the crystal form A before and after the DVS test in the hygroscopicity investigation test of the crystal form A of compound 1.
- Figure 15 shows the comparison of XRPD patterns after heating to different temperatures (30°C, 92°C, 118°C, 132°C, 175°C, respectively) and cooling of the crystalline form A of compound 1 under the protection of nitrogen.
- Figure 16 shows the 1 H NMR spectrum of the hydrate crystal form B of Compound 1.
- Figure 17 shows the 1 H NMR spectrum of the hydrate crystal form C of Compound 1.
- Figure 18 shows the 1 H NMR spectrum of the dichloromethane solvate form D of Compound 1.
- Figure 19 shows the 1 H NMR spectrum of the isopropanol solvate form E of Compound 1.
- Figure 20 shows the comparison of XRPD patterns of the hydrate crystalline form B of compound 1 after heating to different temperatures (130°C and 180°C, respectively) and cooling under the protection of nitrogen.
- Figure 21 shows the comparison of XRPD patterns after heating to different temperatures (130°C, 160°C, respectively) and cooling of the hydrate crystal form C of compound 1 under the protection of nitrogen.
- Figure 22 shows the comparison of XRPD patterns of the dichloromethane solvate form D of compound 1 under the protection of nitrogen and heated to different temperatures (100°C and 160°C, respectively) and cooled.
- Figure 23 shows the comparison of XRPD patterns of isopropanol solvate form E of compound 1 after heating to different temperatures (96°C and 180°C, respectively) under nitrogen protection and cooling.
- the compound 1 described in this application is the compound 6 of Example 6 described in the PCT Patent Application Publication No. WO2020094018, and its synthesis is described in detail in the Example 6 of the PCT Patent Application.
- the compound 1 described in this application also covers all tautomeric forms and isotopic substitution forms of compound 1.
- solvate refers to a complex formed by combining compound 1 with a solvent, which contains a stoichiometric or non-stoichiometric solvent. If the solvent is water, the solvate is a hydrate. Examples of solvents that can form solvates include, but are not limited to, water, isopropanol, dichloromethane, methanol, ethanol, ethyl acetate, and the like.
- pharmaceutically acceptable refers to a compound, material, composition and/or dosage form that is suitable for use in contact with human and animal tissues within the scope of reasonable medical judgment without excessive Toxicity, irritation, allergic reactions or other problems or complications are commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable carrier refers to a pharmaceutically acceptable material, composition or vehicle, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials, which Involving the carrying or transport of therapeutic agents (for example, Compound 1 and its various crystal forms) from one location, body fluid, tissue, organ (internal or external) or part of the body to another location, body fluid, tissue, organ, or body Part of it without interfering with the structure and properties of the therapeutic agent.
- the pharmaceutically acceptable carrier can be a vehicle, diluent, excipient, or other material that can be used to contact animal tissues without excessive toxicity or side effects.
- Certain such carriers enable therapeutic agents (for example, Compound 1 and its various crystal forms) to be formulated into, for example, tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions, and lozenges for administration The subject of administration takes it orally.
- Certain such carriers enable therapeutic agents (for example, Compound 1 and its various crystal forms) to be formulated for injection, infusion, or topical administration.
- Exemplary pharmaceutically acceptable carriers include sugar, starch, cellulose, malt, tragacanth, gelatin, Ringer's solution, alginic acid, isotonic saline, buffers, and the like.
- the pharmaceutically acceptable carriers that can be used in this application include carriers generally known in the art, such as those disclosed in "Remington Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference. .
- administration refers to the introduction of a therapeutic agent (for example, Compound 1 and its various crystalline forms) into a patient.
- a therapeutic agent for example, Compound 1 and its various crystalline forms
- administration refers to direct administration and/or indirect administration.
- the direct administration can be administered to the patient by a medical professional or the patient himself.
- the indirect administration can be a prescription for drugs the behavior of. For example, the physician instructs the patient to administer the drug himself and/or to provide the patient with a prescription for the drug to administer the drug to the patient. In any case, administration requires delivery of the drug to the patient.
- the term "effective amount” or “therapeutically effective amount” used in this application refers to the amount of a drug that can suppress or alleviate the disease or symptom of a subject or patient, or can prevent or prevent the occurrence of a disease or symptom prophylactically.
- the therapeutically effective amount can be the amount of the drug that relieves one or more diseases or symptoms of the subject or patient to a certain degree; it can be part of one or more physiological or biochemical parameters related to the cause of the disease or symptom Or the amount of the drug that completely returns to normal; and/or the amount of the drug that can reduce the likelihood of disease or symptoms.
- subject or patient refers to an animal that has been or will be the object of treatment, observation, or experiment, including human and non-human animals.
- Non-human animals include all vertebrates, such as mammals and non-mammals.
- Subject or patient can also be livestock animals, such as cattle, pigs, sheep, poultry, and horses; or rodents, such as rats, mice; or primates, such as apes, monkeys; or Domestic animals, such as dogs and cats.
- the subject or patient is a human.
- a "subject in need” refers to a subject who may have or is suspected of having a disease or condition that would benefit from certain treatments.
- the term "substantially pure" used in this application means that the composition containing the crystalline form contains less than 99%, less than 95%, less than 90%, Less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25 %, less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% by weight
- the other substances include other crystal forms and/or impurities.
- the impurities may include by-products, reaction starting materials, reagents from chemical reactions, contaminants, degradation products, water or solvents, etc.
- polymorph refers to different crystal structures (in solvated or unsolvated form) that a compound can crystallize.
- the compound 1 in this application can be crystallized to form different crystal structures, that is, polymorphs.
- C 1-6 alkyl refers to a straight-chain or branched alkyl group containing 1-6 carbon atoms. Specific examples include but are not limited to: methyl, ethyl, n-propyl, Isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl Base, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethyl Butyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1,2-dimethylpropyl, etc. .
- hydroxyl used in this application refers to groups such as -OH.
- ether solvent used in this application refers to a chain compound or cyclic compound containing an ether bond -O- and having 1 to 10 carbon atoms. Specific examples include, but are not limited to: tetrahydrofuran, ethyl ether, propylene glycol methyl Ether, methyl tert-butyl ether or 1,4-dioxane.
- alcoholic solvent used in this application refers to a group derived from one or more "hydroxyl groups” substituting one or more hydrogen atoms on the "C 1-6 alkyl group", the "hydroxyl group” and “"C 1-6 alkyl” is as defined above, and specific examples include but are not limited to: methanol, ethanol, isopropanol, n-propanol, isoamyl alcohol or trifluoroethanol.
- ester solvent used in this application refers to a combination of a lower organic acid with 1 to 4 carbon atoms and a lower alcohol with 1 to 6 carbon atoms. Specific examples include but are not limited to: Ethyl acetate, isopropyl acetate or butyl acetate.
- mixed solvent used in this application refers to a solvent formed by mixing one or more different types of organic solvents in a certain ratio, or a solvent formed by mixing an organic solvent and water in a certain ratio.
- the mixed solvent may be a mixed solvent of alcohols and ethers.
- the mixed solvent of alcohols and ethers may be a mixed solvent of methanol and ether.
- X-ray powder diffraction pattern or "XRPD” as used in this application is an x-y pattern with a diffraction angle (ie °2 ⁇ ) on the x-axis and intensity on the y-axis. The peaks in this spectrum can be used to characterize the solid state of crystals. In the case of any data measurement result, there is variability in XRPD data.
- the data is often uniquely represented by the diffraction angle of the peak, and does not include the intensity of the peak, because the intensity of the peak may be particularly sensitive to sample preparation (for example, particle size, moisture content, solvent content, and preferred orientation effects affect sensitivity) Therefore, samples of the same material prepared under different conditions may produce slightly different patterns; this variability is usually greater than the variability of the diffraction angle.
- the variability of the diffraction angle can also be sensitive to sample preparation.
- Other sources of variability come from the instrument parameters and the processing of the original X-ray data: different X-ray instrument operations use different parameters and these may result in slightly different XRPD patterns from the same solid form, and similarly, different software The package handles X-ray data in different ways and this also leads to variability.
- a variability of ⁇ 0.3°2 ⁇ is usually assigned to the diffraction angle in the XRPD pattern.
- the "about" used when referring to a 2 ⁇ angle means that there can be an error of ⁇ 0.3° on the basis of the mentioned value, for example, it can be -0.30°, -0.29°, -0.28° , -0.27°, -0.26°, -0.25°, -0.24°, -0.23°, -0.22°, -0.21°, -0.20°, -0.19°, -0.18°, -0.17°, -0.16°,- 0.15°, -0.14°, -0.13°, -0.12°, -0.11°, -0.10°, -0.09°, -0.08°, -0.07°, -0.06°, -0.05°,
- interplanar spacing refers to the selection of three non-parallel unit vectors a, b, and c connecting two adjacent lattice points in a spatial lattice, and they divide the lattice
- the parallelepiped units that are juxtaposed are called interplanar spacing.
- the space lattice is divided according to the determined parallelepiped unit lines, and a set of linear grids are obtained, which are called spatial lattices or lattices.
- Lattice and lattice use geometric points and lines to reflect the periodicity of the crystal structure. Different crystal planes have different interplanar distances.
- the unit is Or angstroms.
- DSC differential scanning calorimetry
- thermogravimetric analysis refers to a method of measuring the relationship between the mass of a substance and temperature or time under program-controlled temperature. By analyzing the thermogravimetric curve, it is possible to know the composition, thermal stability, thermal decomposition, and resulting products of the sample and its possible intermediate products, which are related to quality.
- the term “substantially similar” or “essentially like... “Shown” means that the basic feature information or main feature information (for example, main peak position, intensity, etc.) of the map is consistent with the information depicted in the mentioned map, and it is not required that all the features of the map are consistent with the mentioned map.
- the information depicted is exactly the same.
- the application provides a compound 1 represented by formula (I) (ie, (S)-1'-(8-((2-amino-3-chloropyridin-4-yl)thio)imidazole And [1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine) crystalline form A , Compound 1 hydrate crystal form B and hydrate crystal form C, compound 1 dichloromethane solvate crystal form D, and compound 1 isopropanol solvate crystal form E.
- formula (I) ie, (S)-1'-(8-((2-amino-3-chloropyridin-4-yl)thio)imidazole And [1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine
- the present application provides crystalline form A of compound 1.
- the application provides substantially pure Form A of Compound 1.
- Compound 1 has an unsolvated crystal form, for example, the crystal form A is an anhydrate crystal form of Compound 1.
- the XRPD pattern of the crystalline form A has one or more (for example, two, three) peaks selected from the group consisting of about 6.46°, about 12.64°, and about 12.93° 2 ⁇ .
- the XRPD pattern of the crystal form A has a peak at about 6.46° 2 ⁇ .
- the XRPD pattern of the crystal form A has a peak at about 12.64° 2 ⁇ .
- the XRPD pattern of the crystal form A has a peak at approximately 12.93° 2 ⁇ .
- the XRPD pattern of the crystal form A has peaks at about 6.46°2 ⁇ and about 12.64°2 ⁇ .
- the XRPD pattern of the crystal form A has peaks at about 6.46°2 ⁇ and about 12.93°2 ⁇ .
- the XRPD pattern of the crystal form A has peaks at approximately 12.64°2 ⁇ and approximately 12.93°2 ⁇ .
- the XRPD pattern of the crystalline form A has all peaks selected from the group consisting of about 6.46°, about 12.64°, and about 12.93° 2 ⁇ .
- the XRPD pattern of the crystal form A further has one or more (for example, 2, 3, 4, 5, 6) peaks selected from the following group: about 13.50°, About 14.60°, about 16.49°, about 17.66°, about 18.27°, and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 13.50° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 14.60° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 16.49° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 17.66° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 18.27° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 23.04°2 ⁇ .
- the XRPD pattern of the crystalline form A further has two or more (for example, 3, 4, 5, 6) peaks selected from the following group: about 13.50°, about 14.60°, about 16.49°, about 17.66°, about 18.27°, and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at approximately 13.50° 2 ⁇ and approximately 14.60° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ and about 16.49° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ and about 17.66° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ and about 18.27° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at approximately 14.60° 2 ⁇ and approximately 16.49° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at approximately 14.60° 2 ⁇ and approximately 17.66° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at approximately 14.60° 2 ⁇ and approximately 18.27° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at approximately 14.60° 2 ⁇ and approximately 23.04° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 16.49°2 ⁇ and about 17.66°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 16.49°2 ⁇ and about 18.27°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 16.49°2 ⁇ and about 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 17.66°2 ⁇ and about 18.27°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 17.66°2 ⁇ and about 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 18.27°2 ⁇ and about 23.04°2 ⁇ .
- the XRPD pattern of the crystalline form A further has three or more (for example, 4, 5, 6) peaks selected from the following group: about 13.50°, about 14.60°, About 16.49°, about 17.66°, about 18.27°, and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at approximately 13.50°2 ⁇ , approximately 14.60°2 ⁇ , and approximately 16.49°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ , about 14.60° 2 ⁇ , and about 17.66° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ , about 14.60° 2 ⁇ , and about 18.27° 2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at about 13.50°2 ⁇ , about 14.60°2 ⁇ , and about 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ , about 16.49° 2 ⁇ , and about 17.66° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ , about 16.49° 2 ⁇ , and about 18.27° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ , about 16.49° 2 ⁇ , and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50°2 ⁇ , about 17.66°°2 ⁇ , and about 18.27°2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at about 13.50°2 ⁇ , about 17.66°2 ⁇ , and about 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 13.50° 2 ⁇ , about 18.27° 2 ⁇ , and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 14.60° 2 ⁇ , about 16.49° 2 ⁇ , and about 17.66° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at approximately 14.60° 2 ⁇ , approximately 16.49° 2 ⁇ , and approximately 18.27° 2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at approximately 14.60°2 ⁇ , approximately 16.49°2 ⁇ , and approximately 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 14.60° 2 ⁇ , about 17.66° 2 ⁇ , and about 18.27° 2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at about 14.60°2 ⁇ , about 17.66°2 ⁇ , and about 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 14.60° 2 ⁇ , about 18.27° 2 ⁇ , and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 16.49°2 ⁇ , about 17.66°2 ⁇ , and about 18.27°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 16.49°2 ⁇ , about 17.66°2 ⁇ , and about 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 17.66°2 ⁇ , about 18.27°2 ⁇ , and about 23.04°2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at about 16.49°2 ⁇ , about 18.27°2 ⁇ , and about 23.04°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 17.66°2 ⁇ , about 18.27°2 ⁇ , and about 23.04°2 ⁇ .
- the XRPD pattern of the crystalline form A further has all peaks selected from the following group: about 13.50°, about 14.60°, about 16.49°, about 17.66°, about 18.27° and about 23.04° 2 ⁇ .
- the XRPD pattern of the crystalline form A further has one or more (for example, 2, 3, 4) peaks selected from the following group: about 23.61°, about 25.42°, about 25.79 ° and about 27.83°2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 23.61°2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 25.42° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 25.79° 2 ⁇ .
- the XRPD pattern of the crystal form A also has a peak at about 27.83° 2 ⁇ .
- the XRPD pattern of the crystalline form A further has two or more (for example, 3, 4) peaks selected from the following group: about 23.61°, about 25.42°, about 25.79° And about 27.83°2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at about 23.61°2 ⁇ and about 25.42°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 23.61°2 ⁇ and about 25.79°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at approximately 23.61°2 ⁇ and approximately 27.83°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 25.42° 2 ⁇ and about 25.79° 2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 25.42°2 ⁇ and about 27.83°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 25.79°2 ⁇ and about 27.83°2 ⁇ .
- the XRPD pattern of the crystalline form A further has three or more (for example, 4) peaks selected from the following group: about 23.61°, about 25.42°, about 25.79°, and about 27.83° 2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at about 23.61°2 ⁇ , about 25.42°2 ⁇ , and about 25.79°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 23.61°2 ⁇ , about 25.42°2 ⁇ , and about 27.83°2 ⁇ .
- the XRPD pattern of the crystalline form A also has peaks at about 25.42°2 ⁇ , about 25.79°2 ⁇ , and about 27.83°2 ⁇ .
- the XRPD pattern of the crystal form A also has peaks at about 23.61°2 ⁇ , about 25.79°2 ⁇ , and about 27.83°2 ⁇ .
- the XRPD pattern of the crystal form A further has all peaks selected from the group consisting of about 23.61°, about 25.42°, about 25.79° and about 27.83° 2 ⁇ .
- the XRPD pattern of the crystal form A has all peaks selected from the following group:
- the XRPD pattern of the crystal form A is substantially similar to the XRPD pattern depicted in FIG. 1. In some embodiments, the XRPD pattern of the crystal form A is shown in FIG. 1. In some embodiments, the crystal form A has at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least XRPD patterns of 10, at least 11, at least 12, and at least 13 2 ⁇ angles.
- the DSC spectrum of the crystalline form A includes an endothermic peak at about 262.0°C (peak temperature). In some embodiments, the DSC spectrum of the crystal form A further includes an exothermic peak at about 153.7°C (peak temperature). In some embodiments, the DSC profile of the crystal form A is substantially similar to the DSC profile depicted in FIG. 2. In some embodiments, the DSC spectrum of the crystal form A is shown in FIG. 2.
- the TGA pattern of the crystal form A shows that when heated to about 120°C, the weight loss of the sample is about 1.5% to 2.0%, for example, about 1.5%, about 1.6%, about 1.61%, about 1.62% , About 1.63%, about 1.64%, about 1.65%, about 1.66%, about 1.67%, 1.68%, about 1.69%, about 1.70%, about 1.71%, about 1.72%, about 1.8%, about 1.9%, about 2.0 %.
- the TGA pattern of the crystalline form A shows that when heated to 120° C., the weight loss of the sample is about 1.69%.
- the TGA pattern of the crystal form A is substantially similar to the TGA pattern depicted in FIG. 2. In some embodiments, the TGA pattern of the crystal form A is shown in FIG. 2.
- the crystal form A is applicable to at least one, two or three of the following (a) to (c):
- the crystal form A has an XRPD pattern basically as shown in Figure 1;
- the crystal form A has a TGA pattern substantially as shown in FIG. 2.
- the crystal form A basically has the following characteristics:
- the crystal form A has an XRPD pattern basically as shown in Figure 1;
- the crystal form A has a TGA pattern substantially as shown in FIG. 2.
- the crystal form A is substantially pure, for example, the purity of the crystal form A is greater than 90 wt%, greater than 91 wt%, greater than 92 wt%, greater than 93 wt%, greater than 94 wt%, greater than 95 wt% , Greater than 96 wt%, greater than 97 wt%, greater than 98 wt%, or greater than 99 wt%.
- the purity of the crystal form A is determined by high performance liquid chromatography (HPLC).
- compound 1 contains no more than about 5.0 area percent HPLC total organic impurities; in some embodiments, it contains no more than about 3.0 area percent HPLC total organic impurities; in some implementations In the method, it contains not more than about 1.5 area percent HPLC total organic impurities. In other embodiments, relative to the total area of the HPLC chromatogram, compound 1 contains no more than about 1.0 area percent HPLC any single impurity; no more than about 0.6 area percent HPLC any single impurity; in some embodiments, no Any single impurity that is greater than about 0.5 area percent HPLC.
- the ratio of the HPLC purity of the crystalline form A to the initial HPLC purity of the crystalline form A after being placed at 60°C/closed conditions for 24 hours is greater than 99%, for example, greater than 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or higher.
- the ratio of the HPLC purity of the crystalline form A to the initial HPLC purity of the crystalline form A after being left open for 1 week at 25°C/60%RH is greater than 99%, for example, greater than 99.1% , 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or higher.
- the ratio of the HPLC purity of the crystalline form A to the initial HPLC purity of the crystalline form A after being left open at 40°C/75%RH for 1 week is greater than 99%, for example, greater than 99.1% , 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or higher.
- the present application provides crystalline form B of compound 1.
- the application provides substantially pure Form B of Compound 1.
- the crystal form B is the hydrate crystal form of compound 1.
- the XRPD pattern of the crystalline form B has one or more (for example, two, three) peaks selected from the following group: about 7.36°, about 10.82°, and about 11.10° 2 ⁇ .
- the XRPD pattern of the crystalline form B has a peak at about 7.36° 2 ⁇ .
- the XRPD pattern of the crystal form B has a peak at about 10.82° 2 ⁇ .
- the XRPD pattern of the crystal form B has a peak at about 11.10° 2 ⁇ .
- the XRPD pattern of the crystal form B has peaks at about 7.36°2 ⁇ and about 10.82°2 ⁇ .
- the XRPD pattern of the crystal form B has peaks at about 7.36° 2 ⁇ and about 11.10° 2 ⁇ .
- the XRPD pattern of the crystal form B has peaks at about 10.82° 2 ⁇ and about 11.10° 2 ⁇ .
- the XRPD pattern of the crystalline form B has all peaks selected from the group consisting of about 7.36°, about 10.82°, and about 11.10° 2 ⁇ .
- the XRPD pattern of the crystalline form B further has one or more (for example, 2, 3, 4) peaks selected from the following group: about 14.70°, about 15.99°, about 20.96 ° and about 23.78°2 ⁇ .
- the XRPD pattern of the crystalline form B also has a peak at about 14.70° 2 ⁇ .
- the XRPD pattern of the crystal form B also has a peak at about 15.99° 2 ⁇ .
- the XRPD pattern of the crystal form B also has a peak at about 20.96° 2 ⁇ .
- the XRPD pattern of the crystal form B also has a peak at about 23.78°2 ⁇ .
- the XRPD pattern of the crystalline form B further has two or more (for example, 3, 4) peaks selected from the following group: about 14.70°, about 15.99°, about 20.96° And about 23.78°2 ⁇ .
- the XRPD pattern of the crystalline form B also has peaks at approximately 14.70° 2 ⁇ and approximately 15.99° 2 ⁇ .
- the XRPD pattern of the crystal form B also has peaks at approximately 14.70° 2 ⁇ and approximately 20.96° 2 ⁇ .
- the XRPD pattern of the crystal form B also has peaks at approximately 14.70° 2 ⁇ and approximately 23.78° 2 ⁇ .
- the XRPD pattern of the crystal form B also has peaks at approximately 15.99° 2 ⁇ and approximately 20.96° 2 ⁇ .
- the XRPD pattern of the crystal form B also has peaks at approximately 15.99° 2 ⁇ and approximately 23.78° 2 ⁇ .
- the XRPD pattern of the crystal form B also has peaks at about 20.96°2 ⁇ and about 23.78°2 ⁇ .
- the XRPD pattern of the crystalline form B further has three or more (for example, 4) peaks selected from the group consisting of about 14.70°, about 15.99°, about 20.96°, and about 23.78° 2 ⁇ .
- the XRPD pattern of the crystalline form B also has peaks at about 14.70°, about 15.99°, and about 20.96° 2 ⁇ .
- the XRPD pattern of the crystal form B also has peaks at about 14.70° 2 ⁇ , about 15.99° 2 ⁇ , and about 23.78° 2 ⁇ .
- the XRPD pattern of the crystalline form B also has peaks at approximately 14.70°2 ⁇ , approximately 20.96°2 ⁇ , and approximately 23.78°2 ⁇ .
- the XRPD pattern of the crystalline form B also has peaks at about 15.99°2 ⁇ , about 20.96°2 ⁇ , and about 23.78°2 ⁇ .
- the XRPD pattern of the crystalline form B further has all peaks selected from the group consisting of about 14.70°, about 15.99°, about 20.96°, and about 23.78° 2 ⁇ .
- the XRPD pattern of the crystal form B has all peaks selected from the following group:
- the XRPD pattern of the crystalline form B is substantially similar to the XRPD pattern depicted in FIG. 3. In some embodiments, the XRPD pattern of the crystal form B is shown in FIG. 3. In some embodiments, the crystal form B has at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least XRPD patterns of 10, at least 11, at least 12, and at least 13 2 ⁇ angles. In some embodiments, the DSC spectrum of the crystalline form B includes endothermic peaks at about 113.5°C (peak temperature) and about 266.8°C (peak temperature). In some embodiments, the DSC spectrum of the crystalline form B further includes an exothermic peak at about 161.8° C. (peak temperature). In some embodiments, the DSC profile of the crystalline form B is substantially similar to the DSC profile depicted in FIG. 4. In some embodiments, the DSC spectrum of the crystal form B is shown in FIG. 4.
- the TGA pattern of the crystal form B shows that when heated to 120° C., the weight loss of the sample is about 10% to 14%, for example, about 10%, about 11%, about 12%, about 12.1%, About 12.2%, about 12.3%, about 12.4%, about 12.5%, about 12.6%, about 12.7%, about 12.75%, about 12.8%, about 12.9%, about 13%, about 14%.
- the TGA pattern of the crystalline form B shows that the weight loss of the sample is about 12.75% when heated to 120°C.
- the TGA pattern of the crystal form B is substantially similar to the TGA pattern depicted in FIG. 4. In some embodiments, the TGA pattern of the crystal form B is shown in FIG. 4.
- the molar ratio of water molecules to compound 1 in the crystal form B is about 3.9:1, for example, 3:1, 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, 3.9:1, 4:1, 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.5:1, 4.6:1, 4.7: 1. 4.8:1, 4.9:1, or 5:1, or any ratio between any of the above ranges.
- the 1 H NMR spectrum of the crystal form B is substantially similar to the 1 H NMR spectrum shown in FIG. 16. In some embodiments, the 1 H NMR spectrum of the crystal form B is shown in FIG. 16.
- the crystal form B is applicable to at least one, two, three or four of the following (a) to (d):
- the crystal form B has an XRPD pattern substantially as shown in Figure 3;
- the crystal form B has a DSC spectrum substantially as shown in Fig. 4;
- the crystal form B has a TGA pattern substantially as shown in FIG. 4;
- the crystal form B has a 1 H NMR spectrum substantially as shown in FIG. 16.
- the crystal form B basically has the following characteristics:
- the crystal form B has an XRPD pattern substantially as shown in Figure 3;
- the crystal form B has a DSC spectrum substantially as shown in Figure 4.
- the crystal form B has a TGA pattern substantially as shown in FIG. 4.
- the crystal form B basically has the following characteristics:
- the crystal form B has an XRPD pattern substantially as shown in Figure 3;
- the crystal form B has a DSC spectrum substantially as shown in Fig. 4;
- the crystal form B has a TGA pattern substantially as shown in FIG. 4;
- the crystal form B has a 1 H NMR spectrum substantially as shown in FIG. 16.
- the crystal form B is substantially pure, for example, the purity of the crystal form B is greater than 90 wt%, greater than 91 wt%, greater than 92 wt%, greater than 93 wt%, greater than 94 wt%, greater than 95 wt% , Greater than 96 wt%, greater than 97 wt%, greater than 98 wt%, or greater than 99 wt%.
- the purity of the crystal form B is determined by high performance liquid chromatography (HPLC).
- compound 1 contains no more than about 5.0 area percent HPLC total organic impurities; in some embodiments, it contains no more than about 3.0 area percent HPLC total organic impurities; in some implementations In the method, it contains not more than about 1.5 area percent HPLC total organic impurities. In other embodiments, relative to the total area of the HPLC chromatogram, compound 1 contains no more than about 1.0 area percent HPLC any single impurity; no more than about 0.6 area percent HPLC any single impurity; in some embodiments, no Any single impurity that is greater than about 0.5 area percent HPLC.
- the application provides Form C of Compound 1. In certain embodiments, the application provides substantially pure Form C of Compound 1. In certain embodiments, the crystal form C is the hydrate crystal form of compound 1.
- the XRPD pattern of the crystalline form C has one or more (for example, two, three) peaks selected from the following group: about 7.33°, about 11.08°, and about 14.70° 2 ⁇ .
- the XRPD pattern of the crystal form C has a peak at about 7.33° 2 ⁇ .
- the XRPD pattern of the crystal form C has a peak at about 11.08°2 ⁇ .
- the XRPD pattern of the crystal form C has a peak at about 14.70° 2 ⁇ .
- the XRPD pattern of the crystal form C has peaks at about 7.33°2 ⁇ and about 11.08°2 ⁇ .
- the XRPD pattern of the crystal form C has peaks at about 7.33° 2 ⁇ and about 14.70° 2 ⁇ .
- the XRPD pattern of the crystalline form C has peaks at approximately 11.08°2 ⁇ and approximately 14.70°2 ⁇ .
- the XRPD pattern of the crystalline form C has all peaks selected from the group consisting of about 7.33°, about 11.08°, and about 14.70° 2 ⁇ .
- the XRPD pattern of the crystalline form C further has one or more (for example, 2, 3, 4, 5) peaks selected from the following group: about 16.23°, about 18.85° , About 21.20°, about 22.03° and about 24.33°2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 16.23° 2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 18.85° 2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 21.20° 2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 22.03° 2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 24.33° 2 ⁇ .
- the XRPD pattern of the crystal form C further has two or more (for example, 3, 4, 5) peaks selected from the following group: about 16.23°, about 18.85°, About 21.20°, about 22.03° and about 24.33° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 16.23° 2 ⁇ and about 18.85° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 16.23° 2 ⁇ and about 21.20° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 16.23°2 ⁇ and about 22.03°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 16.23°2 ⁇ and about 24.33°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 18.85° 2 ⁇ and about 21.20° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 18.85° 2 ⁇ and about 22.03° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 18.85° 2 ⁇ and about 24.33° 2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 21.20°2 ⁇ and about 22.03°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 21.20° 2 ⁇ and about 24.33° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 22.03°2 ⁇ and about 24.33°2 ⁇ .
- the XRPD pattern of the crystalline form C further has three or more (for example, 4, 5) peaks selected from the following group: about 16.23°, about 18.85°, about 21.20° , About 22.03° and about 24.33°2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 16.23°2 ⁇ , about 18.85°2 ⁇ , and about 21.20°2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 16.23°2 ⁇ , about 18.85°2 ⁇ , and about 22.03°2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 16.23°2 ⁇ , about 18.85°2 ⁇ , and about 24.33°2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 16.23°2 ⁇ , about 21.20°2 ⁇ , and about 22.03°2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 16.23°2 ⁇ , about 21.20°2 ⁇ , and about 24.33°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 16.23°2 ⁇ , about 22.03°2 ⁇ , and about 24.33°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 18.85° 2 ⁇ , about 21.20° 2 ⁇ , and about 22.03° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 18.85° 2 ⁇ , about 21.20° 2 ⁇ , and about 24.33° 2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 21.20°2 ⁇ , about 22.03°2 ⁇ , and about 24.33°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 18.85°2 ⁇ , about 22.03°2 ⁇ , and about 24.33°2 ⁇ .
- the XRPD pattern of the crystal form C further has all peaks selected from the group consisting of about 16.23°, about 18.85°, about 21.20°, about 22.03°, and about 24.33° 2 ⁇ .
- the XRPD pattern of the crystalline form C further has one or more (for example, 2, 3, 4) peaks selected from the following group: about 15.20°, about 20.05°, about 23.70 ° and about 29.13°2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 15.20° 2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 20.05° 2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 23.70° 2 ⁇ .
- the XRPD pattern of the crystal form C also has a peak at about 29.13° 2 ⁇ .
- the XRPD pattern of the crystalline form C further has two or more (for example, 3, 4) peaks selected from the following group: about 15.20°, about 20.05°, about 23.70° And about 29.13°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 15.20° 2 ⁇ and about 20.05° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at approximately 15.20° 2 ⁇ and approximately 23.70° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at approximately 15.20° 2 ⁇ and approximately 29.13° 2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 20.05°2 ⁇ and about 23.70°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 20.05°2 ⁇ and about 29.13°2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 23.70°2 ⁇ and about 29.13°2 ⁇ .
- the XRPD pattern of the crystalline form C further has three or more (for example, 4) peaks selected from the group consisting of: about 15.20°, about 20.05°, about 23.70°, and about 29.13° 2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 15.20°2 ⁇ , about 20.05°2 ⁇ , and about 23.70°2 ⁇ .
- the XRPD pattern of the crystalline form C also has peaks at about 15.20°2 ⁇ , about 20.05°2 ⁇ , and about 29.13°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 20.05°2 ⁇ , about 23.70°2 ⁇ , and about 29.13°2 ⁇ .
- the XRPD pattern of the crystal form C also has peaks at about 15.20° 2 ⁇ , about 23.70° 2 ⁇ , and about 29.13° 2 ⁇ .
- the XRPD pattern of the crystal form C further has all peaks selected from the group consisting of about 15.20°, about 20.05°, about 23.70° and about 29.13° 2 ⁇ .
- the XRPD pattern of the crystal form C has all peaks selected from the following group:
- the XRPD pattern of the crystalline form C is substantially similar to the XRPD pattern depicted in FIG. 5. In some embodiments, the XRPD pattern of the crystal form C is shown in FIG. 5. In some embodiments, the crystal form C has at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least XRPD patterns of 10, at least 11, at least 12, and at least 13 2 ⁇ angles. In some embodiments, the DSC spectrum of the crystalline form C includes endothermic peaks at about 117.2°C (peak temperature) and about 265.6°C (peak temperature). In some embodiments, the DSC spectrum of the crystal form C further includes an endothermic peak at about 46.4° C. (peak temperature).
- the DSC spectrum of the crystalline form C further includes an exothermic peak at about 147.0°C (peak temperature).
- the DSC profile of the crystal form C is substantially similar to the DSC profile depicted in FIG. 6.
- the DSC spectrum of the crystal form C is shown in FIG. 6.
- the TGA pattern of the crystal form C shows that when heated to 120° C., the weight loss of the sample is about 10% to 14%, for example, about 10%, about 11%, about 11.5%, about 12%, About 12.1%, about 12.2%, about 12.3%, about 12.4%, about 12.5%, about 12.6%, about 12.7%, about 12.8%, about 12.9%, about 13%, about 13.5%, about 14%.
- the TGA pattern of the crystalline form C shows that when heated to 120° C., the weight loss of the sample is about 12.23%.
- the TGA pattern of the crystal form C is substantially similar to the TGA pattern depicted in FIG. 6. In some embodiments, the TGA pattern of the crystal form C is shown in FIG. 6.
- the molar ratio of water molecules to compound 1 in the crystal form C is about 3.7:1, for example, 3:1, 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, 3.9:1, 4:1, 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.5:1, 4.6:1, 4.7: 1, 4.8:1, 4.9:1, or 5:1.
- the 1 H NMR spectrum of the crystal form C is substantially similar to the 1 H NMR spectrum shown in FIG. 17. In some embodiments, the 1 H NMR spectrum of the crystal form C is shown in FIG. 17.
- the crystal form C is applicable to at least one, two, three, or four of the following (a) to (d):
- the crystal form C has a DSC spectrum substantially as shown in FIG. 6;
- the crystal form C has a TGA pattern substantially as shown in FIG. 6;
- the crystal form C basically has the following characteristics:
- the crystal form C has a DSC spectrum substantially as shown in FIG. 6;
- the crystal form C has a TGA pattern substantially as shown in FIG. 6.
- the crystal form C basically has the following characteristics:
- the crystal form C has a DSC spectrum substantially as shown in FIG. 6;
- the crystal form C has a TGA pattern substantially as shown in FIG. 6;
- the crystal form C is substantially pure, for example, the purity of the crystal form C is greater than 90 wt%, greater than 91 wt%, greater than 92 wt%, greater than 93 wt%, greater than 94 wt%, greater than 95 wt% , Greater than 96 wt%, greater than 97 wt%, greater than 98 wt%, or greater than 99 wt%.
- the purity of the crystal form C is determined by high performance liquid chromatography (HPLC).
- compound 1 contains no more than about 5.0 area percent HPLC total organic impurities; in some embodiments, it contains no more than about 3.0 area percent HPLC total organic impurities; in some implementations In the method, it contains not more than about 1.5 area percent HPLC total organic impurities. In other embodiments, relative to the total area of the HPLC chromatogram, compound 1 contains no more than about 1.0 area percent HPLC any single impurity; no more than about 0.6 area percent HPLC any single impurity; in some embodiments, no Any single impurity that is greater than about 0.5 area percent HPLC.
- the present application provides crystalline form D of compound 1.
- the present application provides substantially pure Form D of Compound 1.
- the crystal form D is a crystalline form of a solvate of compound 1.
- the crystalline form D is the dichloromethane solvate crystalline form of Compound 1.
- the XRPD pattern of the crystalline form D has one or more (for example, two, three) peaks selected from the following group: about 8.24°, about 13.46°, and about 15.32° 2 ⁇ .
- the XRPD pattern of the crystal form D has a peak at about 8.24° 2 ⁇ .
- the XRPD pattern of the crystal form D has a peak at about 13.46° 2 ⁇ .
- the XRPD pattern of the crystal form D has a peak at about 15.32° 2 ⁇ .
- the XRPD pattern of the crystalline form D has peaks at about 8.24°2 ⁇ and about 13.46°2 ⁇ .
- the XRPD pattern of the crystal form D has peaks at about 8.24°2 ⁇ and about 15.32°2 ⁇ .
- the XRPD pattern of the crystalline form D has peaks at about 13.46°2 ⁇ and about 15.32°2 ⁇ .
- the XRPD pattern of the crystalline form D has all peaks selected from the group consisting of about 8.24°, about 13.46°, and about 15.32° 2 ⁇ .
- the XRPD pattern of the crystalline form D further has one or more (for example, two, three) peaks selected from the following group: about 12.89°, about 15.90°, and about 16.84° 2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at approximately 12.89° 2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at about 15.90° 2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at about 16.84° 2 ⁇ .
- the XRPD pattern of the crystalline form D further has two or more (for example, three) peaks selected from the group consisting of about 12.89°, about 15.90°, and about 16.84° 2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at approximately 12.89° 2 ⁇ and approximately 15.90° 2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at approximately 12.89°2 ⁇ and approximately 16.84°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at approximately 15.90° 2 ⁇ and approximately 16.84° 2 ⁇ .
- the XRPD pattern of the crystalline form D further has all peaks selected from the group consisting of about 12.89°, about 15.90°, and about 16.84° 2 ⁇ .
- the XRPD pattern of the crystalline form D further has one or more (for example, 2, 3, 4, 5) peaks selected from the following group: about 18.45°, about 21.83° , About 23.08°, about 23.80° and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at about 18.45° 2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at about 21.83° 2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at about 23.08°2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at about 23.80° 2 ⁇ .
- the XRPD pattern of the crystal form D also has a peak at about 25.59° 2 ⁇ .
- the XRPD pattern of the crystalline form D further has two or more (for example, 3, 4, 5) peaks selected from the following group: about 18.45°, about 21.83°, About 23.08°, about 23.80° and about 25.59° 2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 18.45° 2 ⁇ and about 21.83° 2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45°2 ⁇ and about 23.08°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45° 2 ⁇ and about 23.80° 2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45°2 ⁇ and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 21.83° 2 ⁇ and about 23.08° 2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 21.83° 2 ⁇ and about 23.80° 2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 21.83° 2 ⁇ and about 25.59° 2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 23.08°2 ⁇ and about 23.80°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 23.08°2 ⁇ and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 23.80°2 ⁇ and about 25.59°2 ⁇ .
- the XRPD pattern of the crystalline form D further has three or more (for example, 4, 5) peaks selected from the following group: about 18.45°, about 21.83°, about 23.08° , About 23.80° and about 25.59°2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 18.45°2 ⁇ , about 21.83°2 ⁇ , and about 23.08°2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 18.45°2 ⁇ , about 21.83°2 ⁇ , and about 23.80°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45°2 ⁇ , about 21.83°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45°2 ⁇ , about 23.08°2 ⁇ , and about 23.80°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45°2 ⁇ , about 23.08°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 18.45°2 ⁇ , about 23.80°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 21.83° 2 ⁇ , about 23.08° 2 ⁇ , and about 23.80° 2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 21.83°2 ⁇ , about 23.08°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 21.83°2 ⁇ , about 23.80°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 23.08°2 ⁇ , about 23.80°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystalline form D further has four or more (for example, 5) peaks selected from the following group: about 18.45°, about 21.83°, about 23.08°, about 23.80 ° and about 25.59°2 ⁇ .
- the XRPD pattern of the crystalline form D also has peaks at about 18.45°2 ⁇ , about 21.83°2 ⁇ , about 23.08°2 ⁇ , and about 23.80°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45°2 ⁇ , about 21.83°2 ⁇ , about 23.08°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 18.45°2 ⁇ , about 21.83°2 ⁇ , about 23.80°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystal form D also has peaks at about 21.83°2 ⁇ , about 23.08°2 ⁇ , about 23.80°2 ⁇ , and about 25.59°2 ⁇ .
- the XRPD pattern of the crystalline form D further has all peaks selected from the group consisting of about 18.45°, about 21.83°, about 23.08°, about 23.80°, and about 25.59° 2 ⁇ .
- the XRPD pattern of the crystal form D has all peaks selected from the following group:
- the XRPD pattern of the crystalline form D is substantially similar to the XRPD pattern depicted in FIG. 7. In some embodiments, the XRPD pattern of the crystal form D is shown in FIG. 7. In some embodiments, the crystal form D has at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least XRPD patterns of 10, at least 11, at least 12, and at least 13 2 ⁇ angles. In some embodiments, the DSC spectrum of the crystalline form D includes an endothermic peak at about 124.1°C (peak temperature). In some embodiments, the DSC spectrum of the crystalline form D further includes an endothermic peak at about 59.8°C (peak temperature).
- the DSC spectrum of the crystalline form D further includes an endothermic peak at about 129.8°C (peak temperature).
- the DSC spectrum of the crystal form D is substantially similar to the DSC spectrum shown in FIG. 8.
- the DSC spectrum of the crystal form D is shown in FIG. 8.
- the TGA pattern of the crystal form D shows that when heated to 150° C., the weight loss of the sample is about 11% to 15%, for example, about 11%, 11.5%, 12%, 12.5%, 13%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 14%, 14.5%, 15%.
- the TGA pattern of the crystalline form D shows that when heated to 150° C., the weight loss of the sample is about 13.08%.
- the TGA pattern of the crystal form D is substantially similar to the TGA pattern depicted in FIG. 8. In some embodiments, the TGA pattern of the crystal form D is shown in FIG. 8.
- the molar ratio of dichloromethane molecules to compound 1 in the crystal form D is about 0.8:1, for example, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9: 1, 1:1, 1.1:1 or 1.2:1.
- the 1 H NMR spectrum of the crystal form D is substantially similar to the 1 H NMR spectrum depicted in FIG. 18. In some embodiments, the 1 H NMR spectrum of the crystal form D is shown in FIG. 18.
- the crystal form D is applicable to at least one, two, three or four of the following (a) to (d):
- the crystal form D has an XRPD pattern substantially as shown in FIG. 7;
- the crystal form D has a DSC spectrum substantially as shown in FIG. 8;
- the crystal form D has a TGA pattern substantially as shown in FIG. 8;
- the crystal form D has a 1 H NMR spectrum substantially as shown in FIG. 18.
- the crystal form D basically has the following characteristics:
- the crystal form D has an XRPD pattern substantially as shown in FIG. 7;
- the crystal form D has a DSC spectrum substantially as shown in FIG. 8;
- the crystal form D has a TGA pattern substantially as shown in FIG. 8.
- the crystal form B basically has the following characteristics:
- the crystal form D has an XRPD pattern substantially as shown in FIG. 7;
- the crystal form D has a DSC spectrum substantially as shown in FIG. 8;
- the crystal form D has a TGA pattern substantially as shown in FIG. 8;
- the crystal form D has a 1 H NMR spectrum substantially as shown in FIG. 18.
- the crystal form D is substantially pure, for example, the purity of the crystal form D is greater than 90 wt%, greater than 91 wt%, greater than 92 wt%, greater than 93 wt%, greater than 94 wt%, greater than 95 wt% , Greater than 96 wt%, greater than 97 wt%, greater than 98 wt%, or greater than 99 wt%.
- the purity of the crystal form D is determined by high performance liquid chromatography (HPLC).
- compound 1 contains no more than about 5.0 area percent HPLC total organic impurities; in some embodiments, it contains no more than about 3.0 area percent HPLC total organic impurities; in some implementations In the method, it contains not more than about 1.5 area percent HPLC total organic impurities. In other embodiments, relative to the total area of the HPLC chromatogram, compound 1 contains no more than about 1.0 area percent HPLC any single impurity; no more than about 0.6 area percent HPLC any single impurity; in some embodiments, no Any single impurity that is greater than about 0.5 area percent HPLC.
- the present application provides crystal form E of compound 1. In certain embodiments, the present application provides substantially pure Form E of Compound 1. In certain embodiments, the crystal form E is a solvate crystal form of compound 1. In certain embodiments, the crystal form E is the isopropanol solvate crystalline form of compound 1.
- the XRPD pattern of the crystal form E has one or more (for example, two, three) peaks selected from the group consisting of about 9.10°, about 13.49°, and about 18.24° 2 ⁇ .
- the XRPD pattern of the crystal form E has a peak at about 9.10° 2 ⁇ .
- the XRPD pattern of the crystal form E has a peak at about 13.49° 2 ⁇ .
- the XRPD pattern of the crystal form E has a peak at about 18.24° 2 ⁇ .
- the XRPD pattern of the crystal form E has peaks at about 9.10°2 ⁇ and about 13.49°2 ⁇ .
- the XRPD pattern of the crystal form E has peaks at about 9.10°2 ⁇ and about 18.24°2 ⁇ .
- the XRPD pattern of the crystal form E has peaks at about 13.49° 2 ⁇ and about 18.24° 2 ⁇ .
- the XRPD pattern of the crystal form E has all peaks selected from the group consisting of about 9.10°, about 13.49°, and about 18.24° 2 ⁇ .
- the XRPD pattern of the crystal form E further has one or more (for example, 2, 3, 4, 5, 6, 7) peaks selected from the following group: about 13.03°, about 20.13°, about 22.63°, about 23.35°, about 25.06°, about 27.51°, and about 29.46° 2 ⁇ .
- the XRPD pattern of the crystal form E also has a peak at about 13.03° 2 ⁇ .
- the XRPD pattern of the crystal form E also has a peak at about 20.13° 2 ⁇ .
- the XRPD pattern of the crystal form E also has a peak at about 22.63° 2 ⁇ .
- the XRPD pattern of the crystal form E also has a peak at about 23.35° 2 ⁇ .
- the XRPD pattern of the crystal form E also has a peak at about 25.06°2 ⁇ .
- the XRPD pattern of the crystal form E also has a peak at about 27.51°2 ⁇ .
- the XRPD pattern of the crystal form E also has a peak at about 29.46°2 ⁇ .
- the XRPD pattern of the crystal form E further has two or more (for example, 3, 4, 5, 6, 7) peaks selected from the group consisting of: about 13.03 °, about 20.13°, about 22.63°, about 23.35°, about 25.06°, about 27.51°, and about 29.46° 2 ⁇ .
- the XRPD pattern of the crystalline form E also has peaks at approximately 13.03°2 ⁇ and approximately 20.13°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at approximately 13.03°2 ⁇ and approximately 22.63°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 13.03°2 ⁇ and about 23.35°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 13.03°2 ⁇ and about 25.06°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 13.03°2 ⁇ and about 27.51°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 13.03° 2 ⁇ and about 29.46° 2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 20.13°2 ⁇ and about 22.63°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 20.13°2 ⁇ and about 23.35°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 20.13°2 ⁇ and about 25.06°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 20.13°2 ⁇ and about 27.51°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 20.13°2 ⁇ and about 29.46°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 22.63°2 ⁇ and about 23.35°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 22.63°2 ⁇ and about 25.06°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 22.63°2 ⁇ and about 27.51°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 22.63°2 ⁇ and about 29.46°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 23.35°2 ⁇ and about 25.06°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 23.35°2 ⁇ and about 27.51°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 23.35°2 ⁇ and about 29.46°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 25.06°2 ⁇ and about 27.51°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 25.06°2 ⁇ and about 29.46°2 ⁇ .
- the XRPD pattern of the crystal form E also has peaks at about 27.51°2 ⁇ and about 29.46°2 ⁇ .
- the XRPD pattern of the crystalline form E further has all peaks selected from the following group: about 13.03°, about 20.13°, about 22.63°, about 23.35°, about 25.06°, about 27.51°, and about 29.46 °2 ⁇ .
- the XRPD pattern of the crystal form E has all peaks selected from the following group:
- the XRPD pattern of the crystal form E is substantially similar to the XRPD pattern depicted in FIG. 9. In some embodiments, the XRPD pattern of the crystal form E is shown in FIG. 9. In some embodiments, the crystal form E has at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least XRPD patterns of 10, at least 11, at least 12, and at least 13 2 ⁇ angles.
- the DSC spectrum of the crystalline form E includes an endothermic peak at about 269.0°C (peak temperature). In some embodiments, the DSC spectrum of the crystal form E further includes an endothermic peak at about 123.6° C. (peak temperature). In some embodiments, the DSC spectrum of the crystal form E is substantially similar to the DSC spectrum depicted in FIG. 10. In some embodiments, the DSC spectrum of the crystal form E is shown in FIG. 10.
- the TGA pattern of the crystal form E shows that the weight loss before 100°C is about 4% to 6%, for example, about 4%, about 4.5%, about 4.6%, about 4.7%, about 4.8 %, about 4.9%, about 4.96%, about 5%, about 5.5%, about 6%; the weight loss between 100°C and 150°C is about 11%-14%, for example, about 11%, about 11.5%, About 12%, about 12.1%, about 12.2%, about 12.3%, about 12.4%, about 12.5%, about 12.54%, about 12.6%, about 12.7%, about 12.8%, about 12.9%, about 13%, about 13.5% %, about 14%.
- the TGA pattern of the crystal form E shows that the weight loss before 100°C is about 4.96%, and the weight loss between 100°C and 150°C is about 12.54%. In some embodiments, the TGA pattern of the crystal form E is substantially similar to the TGA pattern depicted in FIG. 10. In some embodiments, the TGA pattern of the crystal form E is shown in FIG. 10. In some embodiments, the molar ratio of isopropanol molecules to compound 1 in the crystal form E is about 1:1, for example, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1: 1, 1.2:1, 1.3:1.
- the 1 H NMR spectrum of the crystal form E is substantially similar to the 1 H NMR spectrum depicted in FIG. 19. In some embodiments, the 1 H NMR spectrum of the crystal form E is shown in FIG. 19.
- the crystal form E is applicable to at least one, two, three or four of the following (a) to (d):
- the crystal form E has an XRPD pattern substantially as shown in Fig. 9;
- the crystal form E has a TGA pattern substantially as shown in FIG. 10;
- the crystal form E basically has the following characteristics:
- the crystal form E has an XRPD pattern substantially as shown in Fig. 9;
- the crystal form E has a DSC spectrum substantially as shown in FIG. 10;
- the crystal form E has a TGA pattern substantially as shown in FIG. 10.
- the crystal form E basically has the following characteristics:
- the crystal form E has an XRPD pattern substantially as shown in Fig. 9;
- the crystal form E has a TGA pattern substantially as shown in FIG. 10;
- the crystal form E is substantially pure, for example, the purity of the crystal form E is greater than 90 wt%, greater than 91 wt%, greater than 92 wt%, greater than 93 wt%, greater than 94 wt%, greater than 95 wt% , Greater than 96 wt%, greater than 97 wt%, greater than 98 wt%, or greater than 99 wt%.
- the purity of the crystal form E is determined by high performance liquid chromatography (HPLC).
- compound 1 contains no more than about 5.0 area percent HPLC total organic impurities; in some embodiments, it contains no more than about 3.0 area percent HPLC total organic impurities; in some implementations In the method, it contains not more than about 1.5 area percent HPLC total organic impurities. In other embodiments, relative to the total area of the HPLC chromatogram, compound 1 contains no more than about 1.0 area percent HPLC any single impurity; no more than about 0.6 area percent HPLC any single impurity; in some embodiments, no Any single impurity that is greater than about 0.5 area percent HPLC.
- this application also provides a method for preparing the crystalline form A-E of Compound 1.
- exemplary methods include, for example, beating method (room temperature or 50°C), gas-solid diffusion method, temperature cycling method, slow volatilization method, gas-liquid diffusion method, polymer induction method, anti-solvent addition method, grinding method Wait.
- the starting material used in the preparation method of the crystal form described in the present application can be compound 1 in any form, such as amorphous, any crystal form, and the like.
- Compound 1 can be prepared by the method disclosed in the PCT patent application with publication number WO2020072656A1 or WO2020094018A1 (which is incorporated herein by reference in its entirety).
- the crystalline form AD of Compound 1 can be prepared by a room temperature beating method.
- compound 1 is dissolved in a first solvent, suspended and stirred at room temperature, and then crystallized, and the crystals are collected by filtration.
- the first solvent may be selected from the following group: ethers (for example, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl methyl ether, anisole, methyl tert-butyl ether, 1,4-dioxane, etc.
- alcohols for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.
- esters for example, ethyl acetate, isopropyl acetate, butyl acetate, etc.
- ketones for example, acetone , Methyl ethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, N-methyl pyrrolidone, etc.
- sulfones for example, dimethyl sulfoxide
- alkanes for example, C 1-7 alkanes, including methane, ethane , Propane, butane, pentane, hexane, n-heptane, etc.
- halogenated hydrocarbons for example, dichloromethane, chloroform, etc.
- acetonitrile water, and mixed solvents formed by any combination thereof.
- the volume ratio of at least two solvents in the mixed solvent can be any ratio, for example, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 95:1 or any two ratio ranges above Any ratio between.
- the mixed solvent may be selected from the following group: isopropyl acetate/chloroform, 2-methyltetrahydrofuran/methanol, cyclopentyl methyl ether/ethanol, isopropanol/dichloromethane, anisole/butanone, ethyl acetate Ester/dimethyl sulfoxide, methyl tert-butyl ether/methanol, n-heptane/chloroform, acetone/water, acetonitrile/methanol, methanol/tetrahydrofuran, 2-butanol/acetonitrile, dichloromethane/n-hexane, 1, 4-Dioxane/ethanol, anisole/chloroform, methyl acetate/methanol, methyl isobutyl ketone/ethanol.
- the crystalline forms A, C and amorphous forms of Compound 1 can be prepared by a 50°C beating method.
- compound 1 is dissolved in a second solvent, suspended and stirred at room temperature, and then crystallized, and the crystals are collected by filtration.
- the second solvent may be selected from the following group: ethers (for example, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl methyl ether, anisole, methyl tert-butyl ether, 1,4-dioxane, etc.
- alcohols for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.
- esters for example, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, etc.
- ketones For example, acetone, methyl ethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, N-methyl pyrrolidone, etc.
- alkanes for example, C 1-7 alkanes, including methane, ethane, propane, butane, pentane Alkane, hexane, n-heptane, etc.
- halogenated hydrocarbons for example, dichloromethane, chloroform, etc.
- acetonitrile water, and mixed solvents formed by any combination thereof.
- the volume ratio of at least two solvents in the mixed solvent can be any ratio, for example, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 95:1 or any two ratio ranges above Any ratio between.
- the mixed solvent may be selected from the following group: methanol/tetrahydrofuran, methyl acetate/methanol, 2-butanol/acetonitrile, dichloromethane/n-hexane, methanol/toluene, 1,4-dioxane/ethanol, tetrahydrofuran /Water, anisole/chloroform, methyl isobutyl ketone/ethanol, acetonitrile/methanol or n-heptane/chloroform.
- the crystalline form A of compound 1 can be prepared by a gas-solid diffusion method. For example, putting compound 1 in a first container, and then placing the first container open in a second container containing a third solvent, the volume of the second container is greater than the volume of the first container, Then the second container was sealed and allowed to stand at room temperature to obtain the crystal form of compound 1.
- the third solvent may be selected from the following group: alcohols (for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.), ethers (for example, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentylmethyl) Ether, anisole, methyl tert-butyl ether, 1,4-dioxane, etc.), esters (e.g., ethyl acetate, isopropyl acetate, butyl acetate, etc.), ketones (e.g., acetone , Methyl ethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, N-methylpyrrolidone, etc.), halogenated hydrocarbons (for example, dichloromethane, chloroform, etc.), acetonitrile, water.
- alcohols for example, methanol, ethanol
- the crystalline forms A and C of compound 1 can be prepared by a temperature cycling method.
- compound 1 is added to the fourth solvent, and the resulting suspension is subjected to cyclic heating and suspension stirring (for example, one cycle is to heat up at 4.5°C/min to 50°C, hold the temperature for 30 minutes, and cool down to 5°C at 0.1°C/min, Constant temperature for 30 min, 3 cycles), crystallize to obtain the crystal form of compound 1.
- the fourth solvent may be selected from the following group: alcohols (for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.), ethers (for example, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentylmethyl) Ether, anisole, methyl tert-butyl ether, 1,4-dioxane, etc.), esters (e.g., ethyl acetate, isopropyl acetate, butyl acetate, etc.), ketones (e.g., acetone , Methyl ethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, N-methyl pyrrolidone, etc.), sulfones (for example, dimethyl sulfoxide), alkanes (for example, C 1-7 alkanes, including methane, ethane ,
- the volume ratio of at least two solvents in the mixed solvent can be any ratio, for example, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 95:1 or any two ratio ranges above Any ratio between.
- the mixed solvent may be selected from the following group: water/dimethylformamide, n-hexane/dimethylsulfoxide, acetonitrile/N-methylpyrrolidone.
- the crystalline forms A-E and amorphous forms of Compound 1 can be prepared by a slow volatilization method.
- compound 1 is added to the fifth solvent to obtain a clear solution, which is slowly volatilized to obtain the crystal form of compound 1.
- the fifth solvent may be selected from the following group: alcohols (for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.), ethers (for example, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentylmethyl) Ether, anisole, methyl tert-butyl ether, 1,4-dioxane, etc.), esters (e.g., ethyl acetate, isopropyl acetate, butyl acetate, etc.), ketones (e.g., acetone , Methyl ethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, N-methyl pyrrolidone, etc.), halogenated hydrocarbons (for example, dichloromethane, chloroform, etc.), acetonitrile, water, and mixed solvents formed by any mixture thereof .
- the volume ratio of at least two solvents in the mixed solvent can be any ratio, for example, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 95:1 or any two ratio ranges above Any ratio between.
- the mixed solvent may be selected from the following group: water/ethanol, ethyl acetate/methanol, acetonitrile/methanol, methyl tert-butyl ether/methanol, acetone/dichloromethane, isopropanol/chloroform.
- the crystalline forms A and C of compound 1 can also be prepared by a gas-liquid diffusion method. For example, put compound 1 in a third container and dissolve it with a sixth solvent, then filter, place the filtrate in the fourth container, and then place the fourth container open in the first container where the anti-solvent of the sixth solvent is placed.
- the volume of the fifth container is greater than the volume of the fourth container, and then the fifth container is sealed and allowed to stand at room temperature to obtain the crystal form of compound 1.
- the sixth solvent may be selected from the following group: alcohols (for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.), ketones (for example, acetone, butanone, methyl ethyl ketone, methyl ethyl ketone, etc.) Isobutyl ketone, N-methylpyrrolidone, etc.), dimethylformamide.
- alcohols for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.
- ketones for example, acetone, butanone, methyl ethyl ketone, methyl ethyl ketone, etc.
- Isobutyl ketone N-methylpyrrolidone, etc.
- dimethylformamide dimethylformamide
- the anti-solvent of the sixth solvent may be selected from the following group: acetonitrile, esters (e.g., ethyl acetate, isopropyl acetate, butyl acetate, etc.), alkanes (e.g., C 1-7 alkanes, including methane, ethane, etc.) Alkane, propane, butane, pentane, hexane (e.g., cyclohexane, n-heptane, etc.).
- esters e.g., ethyl acetate, isopropyl acetate, butyl acetate, etc.
- alkanes e.g., C 1-7 alkanes, including methane, ethane, etc.
- Alkane propane, butane, pentane, hexane (e.g., cyclohexane, n-heptane, etc.).
- the anti-solvent system in the method can be selected from the following group: ethanol/acetonitrile, ethanol/n-heptane, ethanol/ethyl acetate, N-methylpyrrolidone/isopropyl acetate, dimethyl Formamide/acetonitrile, dimethylformamide/cyclohexane.
- the crystalline forms A, D and amorphous forms of Compound 1 can be prepared by a polymer induction method.
- the compound 1 is dissolved in the seventh solvent to obtain a clear solution, and then the mixed polymer is added to the solution and placed at room temperature to evaporate slowly to obtain the crystal form of compound 1.
- the seventh solvent may be selected from the group consisting of alcohols (e.g., methanol, ethanol, n-propanol, isopropanol, butanol, etc.), halogenated hydrocarbons (e.g., dichloromethane, chloroform, etc.), and acetonitrile.
- the mixed polymer can be selected from the following: polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl chloride, polyvinyl acetate, hydroxypropyl methylcellulose and methylcellulose, or a mixture of equal masses, or polycaproic acid Equal quality mixture of ester, polyethylene glycol, polymethyl methacrylate, sodium alginate and hydroxyethyl cellulose.
- the crystalline forms A-C and amorphous forms of Compound 1 can be prepared by an anti-solvent addition method.
- the compound 1 is dissolved in the eighth solvent, and then the anti-solvent of the eighth solvent is added dropwise with stirring, and the crystal form of the compound 1 is obtained by crystallization.
- the eighth solvent may be selected from the following group: alcohols (for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.), halogenated hydrocarbons (for example, dichloromethane, chloroform, etc.), ketones ( For example, acetone, methyl ethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, N-methylpyrrolidone, etc.), sulfones (for example, dimethyl sulfoxide).
- alcohols for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.
- halogenated hydrocarbons for example, dichloromethane, chloroform, etc.
- ketones For example, acetone, methyl ethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, N-methylpyrroli
- the anti-solvent of the eighth solvent can be selected from the following group: toluene, ethers (for example, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl methyl ether, anisole, methyl tert-butyl ether, 1,4- Dioxane, etc.), alcohols (for example, methanol, ethanol, n-propanol, isopropanol, butanol, etc.), esters (for example, ethyl acetate, isopropyl acetate, butyl acetate, etc.), ketones (For example, acetone, methyl ethyl ketone, methyl isobutyl ketone, N-methylpyrrolidone, etc.), water.
- ethers for example, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl methyl ether, anisole, methyl tert-butyl
- the anti-solvent system may be selected from the group consisting of chloroform/toluene, chloroform/ethyl acetate, chloroform/cyclopentyl methyl ether, methanol/water, methanol/tetrahydrofuran, methanol/acetone, dimethyl sulfoxide /Isopropanol, dimethyl sulfoxide/water.
- the crystalline forms A and B of compound 1 can be prepared by grinding methods. For example, compound 1 is placed in a mortar and optionally water is added for grinding to obtain a crystal form of compound 1.
- the preparation method of the crystal form in this application further includes steps such as filtration, washing or drying.
- the present application provides a pharmaceutical composition
- a pharmaceutical composition comprising compound 1 and a pharmaceutically acceptable carrier, said compound 1 having one or more crystal forms selected from the group consisting of crystal form A, hydrate Form B, hydrate form C, dichloromethane solvate form D, and isopropanol solvate form E.
- the crystalline form A, hydrate crystalline form B, hydrate crystalline form C, dichloromethane solvate crystalline form D and isopropanol solvate crystalline form E or pharmaceutical composition of compound 1 of the present application can be formulated as required.
- Required forms such as tablets, capsules, pills, granules, solutions, suspensions, syrups, injections (including injections, sterile powders for injections and concentrated solutions for injections), suppositories, inhalants or sprays Agent.
- the crystalline form A, hydrate crystalline form B, hydrate crystalline form C, dichloromethane solvate crystalline form D and isopropanol solvate crystalline form E or pharmaceutical composition of compound 1 of the present application can be administered in any suitable way
- the method is administered to patients or subjects in need, such as oral, parenteral, rectal, pulmonary or topical administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the crystalline form A, hydrate crystalline form B, hydrate crystalline form C, dichloromethane solvate crystalline form D or isopropanol solvate crystalline form E of compound 1 of the present application are combined with at least one conventional Inert excipients or carriers are mixed, such as sodium citrate or dicalcium phosphate, or mixed with the following ingredients: (a) fillers or compatibilizers, for example, microcrystalline cellulose, starch, lactose, sucrose, glucose, mannitol and Silicic acid; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, such as glycerin; (d) disintegrants , For example, agar, calcium carbonate, potato starch or tapioca starch, alg
- Solid dosage forms can be prepared with coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of active ingredients in such compositions may be released in a certain part of the digestive tract in a delayed manner. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active ingredient can also be formed into a microcapsule form with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
- the liquid dosage form may contain inert diluents (such as water or other solvents), solubilizers and emulsifiers (for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils (especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil), sweeteners (for example, glycerin, propylene glycol, sorbitol, natural Aspartame or sucrose), preservatives, flavor enhancers, colorants, or mixtures of these substances.
- inert diluents such as water or other solvents
- solubilizers and emulsifiers for example, ethanol, isopropanol, ethyl
- compositions for parenteral injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, Ringer's solution of polyols, isotonic sodium chloride solution or mixtures of these substances.
- composition for rectal administration may include suppositories and the like.
- composition for pulmonary administration may include inhalants, sprays, and the like.
- compositions for topical administration may include ointments, powders, patches, propellants, and inhalants.
- the active ingredient is combined with a pharmaceutically acceptable carrier (e.g., animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, Zinc oxide, etc.) and any preservatives, buffers, or propellants that may be required if necessary are mixed together.
- a pharmaceutically acceptable carrier e.g., animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, Zinc oxide, etc.
- pharmaceutically acceptable carriers known in the art can also be included in this application.
- Such carriers are described in, for example, “Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), in “Remington: The Science and Practice of Pharmacy”, Ed. University of the Sciences in Philadelphia, 21 st Edition, LWW (2005), which is incorporated herein by reference in its entirety.
- the crystalline form A, hydrate crystalline form B, hydrate crystalline form C, dichloromethane solvate crystalline form D, and isopropanol solvate crystalline form E of compound 1 of the present application are used to treat and/ Or a preventive effective amount is present in the pharmaceutical composition or medicine.
- the pharmaceutical composition of the application can be formulated as a unit dosage form.
- the content mentioned in this application refers to the equivalent of compound 1 in the free base form, excluding the additional weight generated by the contained solvent (if present in the crystal form).
- the dosage of Form E can be about 0.01 to about 100 mg/kg body weight/day, about 0.05 to about 100 mg/kg body weight/day, about 0.1 to about 100 mg/kg body weight/day, about 0.5 to about 100 mg/kg body weight/day, About 1 to about 100 mg/kg body weight/day, about 1 to about 90 mg/kg body weight/day, about 1 to about 80 mg/kg body weight/day, about 1 to about 70 mg/kg body weight/day, about 1 to about 60 mg/ kg body weight/day, about 1 to about 50 mg/kg body weight/day, about 1 to about 45 mg/kg body weight/day, about 1 to about 40 mg/kg body weight/day, about 1 to about 35 mg/kg body weight/day, or About 1 to about 30 mg/kg body weight/day
- the unit dosage form (eg, tablet, capsule) may contain, for example, about 1-1000 mg, about 1-900 mg, about 1-800 mg, about 1-700 mg, about 1-600 mg, about 1-500 mg, about 1- 400 mg, about 1-300 mg, about 1-200 mg, or about 1-100 mg of the crystal form A, hydrate crystal form B, hydrate crystal form C, dichloromethane solvate crystal form D or isoforms of compound 1 of the present application Propanol Solvate Form E.
- the content of crystal form A, hydrate crystal form B, hydrate crystal form C, dichloromethane solvate crystal form D, and isopropanol solvate crystal form E of compound 1 of the present application in the pharmaceutical composition may depend on a variety of Factors are different, such as potency, biological half-life, disease type and severity, subjects to be treated (such as age and weight), specific administration methods, etc., and those skilled in the art can routinely determine the required content according to needs.
- time and administration time (the time period between doses, the time point of the dose (e.g. before meal, after meal, during meal)) also depend on the subject to be treated, the specific crystal form and its properties (e.g. pharmacokinetics) The nature), the type of disease and its severity, the specific composition and method used are different, and those skilled in the art can determine it routinely according to needs.
- the compound 1 has crystalline form A.
- the compound 1 has crystalline form B.
- the compound 1 of has crystalline form C.
- the compound 1 has crystalline form D.
- the compound 1 of has the crystalline form E.
- the pharmaceutical composition described in the present application further includes other therapeutic agents.
- the other therapeutic agents include anti-cancer drugs, for example, abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol ), altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bevacuzimab, fluorouracil , Bexarotene, bleomycin, bortezomib, busulfan, calusterone, capecitabine, camptothecin, Carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cladribine, clofarabine, cyclophosphate Amide, Cytarabine, Actinomycin D, Darbepoetin Alfa, Daunorubicin, Denileukin, Dexrazoxane, Docetaxel, Small Cran
- this application also provides a method for preparing a pharmaceutical composition, which comprises combining the crystal form A, hydrate crystal form B, hydrate crystal form C, dichloromethane solvate crystal form D, and isoforms of compound 1
- the propanol solvate crystal form E or the crystal form AE of compound 1 prepared by the foregoing method is mixed with a pharmaceutically acceptable carrier.
- the application also provides the use of the crystalline forms A-E of compound 1 and the pharmaceutical composition described in the application in the following:
- the "SHP2-mediated disease or disorder” refers to a disease or disorder related to abnormal SHP2 activity/level, which may be due to abnormal activation or destruction of SHP2 in the subject's body, which causes an abnormal increase in SHP2 activity/level Or lower.
- the SHP2-mediated disease or condition is associated with an abnormal increase in SHP2 activity/level.
- the SHP2-mediated disease or disorder is cancer.
- the cancer is selected from the group consisting of Noonan syndrome, leopard skin syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer , Lung cancer, colon cancer, head cancer, head and neck squamous cell carcinoma, gastric cancer, anaplastic large cell lymphoma, glioblastoma, hepatocellular carcinoma (HCC), acute lymphoblastic leukemia, adrenal cortical cancer, anal cancer, Appendix cancer, astrocytoma, atypical malformation/tumor-like, basal cell carcinoma, cholangiocarcinoma, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumor, brain And spinal cord tumors, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic gran
- the present application also provides a method for treating or preventing SHP2-mediated diseases or conditions, including administering to a subject in need the crystal form A and hydrate crystal form of compound 1 described in this application B, hydrate crystal form C, dichloromethane solvate crystal form D, isopropanol solvate crystal form E, or the pharmaceutical composition described in this application.
- the present application also provides crystal form A, hydrate crystal form B, hydrate crystal form C, dichloromethane solvate crystal form of compound 1 for the treatment or prevention of SHP2-mediated diseases or conditions D.
- the present application also provides a method for inhibiting the activity of SHP2, which includes the following steps: administering an effective amount of the crystalline form AE of compound 1 described in the present application to a subject in need thereof, or The subject in need thereof administers an effective amount of the pharmaceutical composition described in this application.
- Humidity change 0-95-0-95-0%RH, the step is 10%, the judgment standard is that the mass change is less than 0.01% within 10000min
- Example 1.1 With reference to the method of Example 1.1, the methanol in Example 1.1 was replaced with a different solvent (specifically as shown in Table 1), and the obtained solid was determined to be the crystal form A of compound 1 by XRPD detection.
- Example 1.16 Referring to the preparation method of Example 1.16, the chloroform/toluene anti-solvent system in Example 1.16 (specifically shown in Table 2) was replaced with a different anti-solvent system, and the obtained solids were determined to be the crystal form A of compound 1 through XRPD detection.
- Example number Anti-solvent system selected Example 1.17 CHCl 3 /EtOAc Example 1.18 CHCl 3 /CPME Example 1.19 DMSO/IPA
- Example 1.20 With reference to the preparation method of Example 1.20, the isopropanol in Example 1.20 was replaced with a different solvent (specifically as shown in Table 3), and the obtained solid was determined to be the crystal form A of compound 1 by XRPD detection.
- Example 1.37 Referring to the preparation method of Example 1.37, the methanol in Example 1.37 (specifically shown in Table 4) was replaced with a different solvent, and the obtained solid was determined to be the crystal form A of compound 1 by XRPD detection.
- Example number Selected solvent (v:v) Example 1.38 EtOH Example 1.39 CHCl 3 Example 1.40 EtOAc/MeOH, 9:1 Example 1.41 ACN/MeOH, 9:1
- Example 1.42 With reference to the preparation method of Example 1.42, the ethanol in Example 1.42 (specifically shown in Table 5) was replaced with a different solvent, and the obtained solid was determined to be the crystal form A of compound 1 by XRPD detection.
- Example 1.52 With reference to the preparation method of Example 1.52, the water in Example 1.52 (specifically shown in Table 6) was replaced with a different solvent, and the obtained solid was determined to be the crystal form A of Compound 1 by XRPD detection.
- Example number Choose solvent Example 1.53 DCM Example 1.54 EtOH Example 1.55 Acetone Example 1.56 EtOAc Example 1.57 ACN Example 1.58 MTBE Example 1.59 THF
- Example 1.60 With reference to the preparation method of Example 1.60, the ethanol/acetonitrile anti-solvent system in Example 1.60 was replaced with a different anti-solvent system (specifically as shown in Table 7), and XRPD detection confirmed that the obtained solids were all crystal form A of compound 1. .
- Example number Anti-solvent system selected Example 1.61 NMP/IPAc Example 1.62 DMF/ACN Example 1.63 DMF/Cyclohexane
- the composition of the mixed polymer A is: polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl chloride, polyvinyl acetate, hydroxypropyl methyl cellulose and methyl cellulose (mixed with equal mass).
- the obtained solid was collected and subjected to XRPD test, and it was determined that the obtained solid was the crystalline form A of compound 1.
- the DSC spectrum and TGA spectrum of the crystalline form A of Compound 1 are shown in FIG. 2.
- the DSC spectrum shows that the crystalline form A of compound 1 has a very shallow exothermic peak at 153.7°C (peak temperature), followed by a sharp endothermic peak at about 262.0°C (peak temperature), the sharp endothermic peak Corresponds to the melting of crystal form A.
- the TGA chart showed that the weight loss of the crystal form A of compound 1 was 1.69% before 120° C., indicating that the crystal form A of compound 1 was an anhydrate crystal form.
- the hygroscopicity of the crystal form A of compound 1 was evaluated by DVS test.
- the DVS map is shown in Figure 13.
- DVS test results show that the crystalline form A of compound 1 has a moisture absorption weight gain of 1.88% at a relative humidity of 80.0%, indicating that it has a slight hygroscopicity.
- the XRPD patterns of the crystal form A of compound 1 before and after the DVS test are shown in FIG. 14, which shows that the crystal form of the crystal form A is consistent before and after the DVS test.
- the HPLC test results are shown in Figures 11A to 11E. From the HPLC test results, it can be seen that the crystal form A of compound 1 has not undergone significant changes in purity after being placed under the above three stability test conditions, maintaining extremely high purity (about 98%), and exhibiting good chemical stability. sex.
- the XRPD test results are shown in Figure 12. After the crystal form A of compound 1 was placed at 60°C/closed for 24 hours and at 25°C/60%RH for 1 week, there was no crystalline transformation. After being left open for 1 week at 40°C/75%RH, only part of the crystal form A was converted to the hydrate crystal form B.
- the crystalline form A of compound 1 was heated to different temperatures (30°C, 92°C, 118°C, 132°C, and 175°C, respectively) under the protection of nitrogen, and the temperature was lowered to perform the XRPD test.
- the temperature-variable XRPD spectrum is shown in Fig. 15 and the results show that the crystal form A of compound 1 did not undergo a crystalline transformation during the heating process (the small shift observed at high temperature is caused by the lattice stretching at high temperature).
- Example 2.1 With reference to the preparation method of Example 2.1, the methanol/water anti-solvent system in Example 2.1 was replaced with a dimethyl sulfoxide/water anti-solvent system, and the obtained solid was determined to be the crystal form B of compound 1 by XRPD detection.
- the 1 H NMR spectrum of the crystalline form B of compound 1 is shown in FIG. 16. It can be seen from the 1 H NMR spectrum that the crystalline form B of compound 1 did not decompose during the preparation process, and a clear water signal was observed.
- the XRPD pattern of the crystalline form B of compound 1 is shown in FIG. 3, and the peaks in the XRPD pattern and their related intensities and interplanar spacing data are shown in Table 10.
- the DSC spectrum and TGA spectrum of the crystalline form B of compound 1 are shown in FIG. 4.
- the DSC spectrum showed that the crystalline form B of compound 1 had two sharp endothermic peaks at 113.5°C and 266.8°C (peak temperature), and an exothermic peak at 161.8°C (peak temperature).
- the TGA chart showed that the crystal form B of compound 1 had a weight loss of 12.75% before 120°C.
- the crystalline form B of compound 1 was heated to different temperatures (130°C and 180°C, respectively) under the protection of nitrogen, and cooled to room temperature, and then the XRPD test was performed.
- the variable temperature XRPD spectrum is shown in Figure 20. The results show that when the crystalline form B is heated to 130°C and cooled to room temperature, the crystalline form B transforms into an amorphous form; when the crystalline form B is heated to 180°C and cooled to room temperature, The crystal form B is transformed into the crystal form A.
- thermal analysis data, 1 H NMR test and variable temperature XRPD test results of the crystal form B of compound 1, it is speculated that the crystal form B is a hydrate, and the molar ratio of water molecules to compound 1 is about 3.9:1.
- it is first dehydrated and transformed into an amorphous form, and then transformed into crystal form A through high-temperature recrystallization.
- Example 3.1 Refer to the preparation method of Example 3.1, replace the acetone/water in Example 3.1 with 1,4-dioxane/water (4:1, v:v), and XRPD detection confirms that the obtained solid is the crystal form of compound 1.
- Example 3.5 Referring to the preparation method of Example 3.5, the ethanol/n-heptane anti-solvent system in Example 3.5 was replaced with an ethanol/ethyl acetate anti-solvent system, and the obtained solid was determined to be the hydrate crystal form C of compound 1 by XRPD detection.
- the 1 H NMR spectrum of the crystalline form C of compound 1 is shown in FIG. 17. It can be seen from the 1 H NMR spectrum that the crystalline form C of compound 1 did not decompose during the preparation process, and a clear water signal was observed.
- the XRPD pattern of the crystalline form C of Compound 1 is shown in FIG. 5, and the peaks in the XRPD pattern and their related intensities and interplanar spacing data are shown in Table 11.
- the DSC spectrum and TGA spectrum of the crystalline form C of compound 1 are shown in FIG. 6.
- the DSC spectrum showed that the crystalline form C of compound 1 had a very shallow endothermic peak at 46.4°C (peak temperature), followed by two sharp endothermic peaks at 117.2°C and 265.6°C (peak temperature). There is an exothermic peak at 147.0°C (peak temperature).
- the TGA chart showed that the weight loss of Form C of Compound 1 was 12.23% before 120°C.
- the crystalline form C of compound 1 was heated to different temperatures (130°C and 160°C, respectively) under the protection of nitrogen, and cooled to room temperature, and then the XRPD test was performed.
- the variable temperature XRPD spectrum is shown in Figure 21. The results show that when the crystal form C is heated to 130°C and cooled to room temperature, the crystal form C is transformed into an amorphous form; when the crystal form C is heated to 160°C and cooled to room temperature, The crystal form C is transformed into the crystal form A.
- the crystal form C is a hydrate, in which the molar ratio of water molecules to compound 1 is about 3.7:1, which is In the process of high-temperature heating, it is first dehydrated and transformed into an amorphous form, and then transformed into crystal form A through high-temperature recrystallization.
- the 1 H NMR spectrum of the crystalline form D of compound 1 is shown in FIG. 18. It can be seen from the 1 H NMR spectrum that the crystalline form D of compound 1 did not decompose during the preparation process, and a clear dichloromethane signal was observed.
- the DSC spectrum and TGA spectrum of the crystalline form D of compound 1 are shown in FIG. 8.
- the DSC spectrum shows that the crystalline form D of compound 1 has three endothermic peaks at 59.8°C, 124.1°C and 129.8°C (peak temperature).
- the TGA chart showed that the weight loss of the crystal form D of compound 1 was 13.08% before 150°C.
- the crystalline form D of compound 1 was heated to different temperatures (100°C and 160°C, respectively) under the protection of nitrogen, and cooled to room temperature, and then the XRPD test was performed.
- the variable temperature XRPD spectrum is shown in Figure 22. The results show that when the crystal form D is heated to 100°C and cooled to room temperature, the crystallinity decreases significantly; when the crystal form D is heated to 160°C and cooled to room temperature, crystals are observed Diffraction signal of type A.
- the 1 H NMR spectrum of the crystalline form E of compound 1 is shown in FIG. 19. It can be seen from the 1 H NMR spectrum that the crystal form E of compound 1 did not decompose during the preparation process, and a clear isopropanol signal was observed.
- the DSC spectrum and TGA spectrum of the crystalline form E of compound 1 are shown in FIG. 10.
- the DSC spectrum shows that the crystalline form E of compound 1 has two endothermic peaks at 123.6°C and 269.0°C (peak temperature).
- the TGA chart shows that the weight loss of the crystal form E of compound 1 before 100°C is 4.96%, and the weight loss between 100 and 150°C is 12.54%.
- the crystalline form E of compound 1 was heated to different temperatures (96°C and 180°C, respectively) under the protection of nitrogen, and cooled to room temperature, and then the XRPD test was performed.
- the temperature-variable XRPD spectrum is shown in Figure 23. The results show that when the crystal form E is heated to 96°C and cooled to room temperature, a small amount of diffraction signal of the crystal form A is observed; when the crystal form E is heated to 180°C and cooled to room temperature Later, the crystal form E was completely transformed into the crystal form A.
- the crystal form E is an isopropanol solvate, in which the molar ratio of isopropanol molecules to compound 1 is about 1. :1, which is transformed into crystal form A through recrystallization in the process of high temperature heating.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
缩写 | 含义 | 缩写 | 含义 |
MeOH | 甲醇 | DCM | 二氯甲烷 |
EtOH | 乙醇 | Anisole | 苯甲醚 |
THF | 四氢呋喃 | MEK | 甲乙酮 |
ACN | 乙腈 | IPAc | 乙酸异丙酯 |
2-MeTHF | 2-甲基四氢呋喃 | CHCl 3 | 氯仿 |
CPME | 环戊基甲醚 | EtOAc | 乙酸乙酯 |
IPA | 异丙醇 | DMSO | 二甲基亚砜 |
MTBE | 甲基叔丁基醚 | n-Heptane | 正庚烷 |
Acetone | 丙酮 | 1,4-Dioxane | 1,4-二氧六环 |
Methyl acetate | 乙酸甲酯 | 2-Butanol | 2-丁醇 |
n-Hexane | 正己烷 | Toluene | 甲苯 |
NMP | N-甲基吡咯烷酮 | Cyclohexane | 环己烷 |
实施例编号 | 选用的溶剂(v:v) | 实施例编号 | 选用的溶剂(v:v) |
实施例1.2 | EtOH | 实施例1.9 | IPAc/CHCl 3,9:1 |
实施例1.3 | THF | 实施例1.10 | EtOAc/DMSO,9:1 |
实施例1.4 | ACN | 实施例1.11 | MTBE/MeOH,9:1 |
实施例1.5 | 2-MeTHF/MeOH,9:1 | 实施例1.12 | n-Heptane/CHCl 3,9:1 |
实施例1.6 | CPME/EtOH,4:1 | 实施例1.13 | Acetone |
实施例1.7 | IPA/DCM,9:1 | 实施例1.14 | Acetone/H 2O,986:14 |
实施例1.8 | Anisole/MEK,9:1 | 实施例1.15 | Acetone/H 2O,95:5 |
实施例编号 | 选用的反溶剂体系 |
实施例1.17 | CHCl 3/EtOAc |
实施例1.18 | CHCl 3/CPME |
实施例1.19 | DMSO/IPA |
实施例编号 | 选用的溶剂(v:v) |
实施例1.38 | EtOH |
实施例1.39 | CHCl 3 |
实施例1.40 | EtOAc/MeOH,9:1 |
实施例1.41 | ACN/MeOH,9:1 |
实施例编号 | 选用的溶剂(v:v) |
实施例1.43 | 1,4-Dioxane |
实施例1.44 | Anisole |
实施例1.45 | IPA |
实施例1.46 | MIBK |
实施例1.47 | IPAc |
实施例1.48 | MTBE |
实施例1.49 | Toluene |
实施例1.50 | n-Hexane/DMSO,4:1 |
实施例1.51 | ACN/NMP,9:1 |
实施例编号 | 选用溶剂 |
实施例1.53 | DCM |
实施例1.54 | EtOH |
实施例1.55 | Acetone |
实施例1.56 | EtOAc |
实施例1.57 | ACN |
实施例1.58 | MTBE |
实施例1.59 | THF |
实施例编号 | 选用的反溶剂体系 |
实施例1.61 | NMP/IPAc |
实施例1.62 | DMF/ACN |
实施例1.63 | DMF/Cyclohexane |
Claims (77)
- 如权利要求1所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱具有所有选自下组的峰:约6.46°、约12.64°和约12.93°2θ。
- 如权利要求1所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约13.50°、约14.60°、约16.49°、约17.66°、约18.27°和约23.04°2θ。
- 如权利要求3所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约13.50°、约14.60°、约16.49°、约17.66°、约18.27°和约23.04°2θ。
- 如权利要求3所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有三个或更多个选自下组的峰:约13.50°、约14.60°、约16.49°、约17.66°、约18.27°和约23.04°2θ。
- 如权利要求3所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有所有选自下组的峰:约13.50°、约14.60°、约16.49°、约17.66°、约18.27°和约23.04°2θ。
- 如前述权利要求中任一项所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约23.61°、约25.42°、约25.79°和约27.83°2θ。
- 如前述权利要求中任一项所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约23.61°、约25.42°、约25.79°和约27.83°2θ。
- 如前述权利要求中任一项所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有三个或更多个选自下组的峰:约23.61°、约25.42°、约25.79°和约27.83°2θ。
- 如前述权利要求中任一项所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱还具有所有选自下组的峰:约23.61°、约25.42°、约25.79°和约27.83°2θ。
- 如前述权利要求中任一项所述的晶型A,其特征在于,所述晶型A的X-射线粉末衍射图谱如图1所示。
- 如前述权利要求中任一项所述的晶型A,其特征在于,所述晶型A的差示扫描量热(DSC)图谱包括于约262.0℃处的吸热峰。
- 如权利要求13所述的晶型A,其特征在于,所述晶型A的差示扫描量热(DSC)图谱如图2所示。
- 如权利要求15所述的晶型B,其特征在于,所述晶型B的X-射线粉末衍射图谱具有所有选自下组的峰:约7.36°、约10.82°和约11.10°2θ。
- 如权利要求15所述的晶型B,其特征在于,所述晶型B的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约14.70°、约15.99°、约20.96°和约23.78°2θ。
- 如权利要求15所述的晶型B,其特征在于,所述晶型B的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约14.70°、约15.99°、约20.96°和约23.78°2θ。
- 如权利要求15所述的晶型B,其特征在于,所述晶型B的X-射线粉末衍射图谱还具有三个或更多个选自下组的峰:约14.70°、约15.99°、约20.96°和约23.78°2θ。
- 如权利要求15所述的晶型B,其特征在于,所述晶型B的X-射线粉末衍射图谱还具有所有选自下组的峰:约14.70°、约15.99°、约20.96°和约23.78°2θ。
- 如权利要求15-21中任一项所述的晶型B,其特征在于,所述晶型B的X-射线粉末衍射图谱如图3所示。
- 如权利要求15-22中任一项所述的晶型B,其特征在于,所述晶型B的差示扫描量热(DSC)图谱包括于约113.5℃和约266.8℃处的吸热峰。
- 如权利要求23所述的晶型B,其特征在于,所述晶型B的差示扫描量热(DSC)图谱如图4所示。
- 如权利要求15-24中任一项所述的晶型B,其特征在于,在所述晶型B中水分子与所述化合物1的摩尔比为约3.9:1。
- 如权利要求26所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱具有所有选自下组的峰:约7.33°、约11.08°和约14.70°2θ。
- 如权利要求26所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约16.23°、约18.85°、约21.20°、约22.03°和约24.33°2θ。
- 如权利要求26所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约16.23°、约18.85°、约21.20°、约22.03°和约24.33°2θ。
- 如权利要求26所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有三个或更多个选自下组的峰:约16.23°、约18.85°、约21.20°、 约22.03°和约24.33°2θ。
- 如权利要求26所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有所有选自下组的峰:约16.23°、约18.85°、约21.20°、约22.03°和约24.33°2θ。
- 如权利要求26-31中任一项所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约15.20°、约20.05°、约23.70°和约29.13°2θ。
- 如权利要求26-32中任一项所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约15.20°、约20.05°、约23.70°和约29.13°2θ。
- 如权利要求26-33中任一项所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有三个或更多个选自下组的峰:约15.20°、约20.05°、约23.70°和约29.13°2θ。
- 如权利要求26-34中任一项所述的晶型C,其特征在于,所述晶型C的X-射线粉末衍射图谱还具有所有选自下组的峰:约15.20°、约20.05°、约23.70°和约29.13°2θ。
- 如权利要求26-36中任一项所述的晶型C,其特征在于,所述晶型C的 X-射线粉末衍射图谱如图5所示。
- 如权利要求26-37中任一项所述的晶型C,其特征在于,所述晶型C的差示扫描量热(DSC)图谱包括于约117.2℃和约265.6℃处的吸热峰。
- 如权利要求38所述的晶型C,其特征在于,所述晶型C的差示扫描量热(DSC)图谱如图6所示。
- 如权利要求26-39中任一项所述的晶型C,其特征在于,在所述晶型C中水分子与所述化合物1的摩尔比为约3.7:1。
- 如权利要求41所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱具有所有选自下组的峰:约8.24°、约13.46°和约15.32°2θ。
- 如权利要求41所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约12.89°、约15.90°和约16.84°2θ。
- 如权利要求41所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约12.89°、约15.90°和约16.84°2θ。
- 如权利要求41所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱还具有所有选自下组的峰:约12.89°、约15.90°和约16.84°2θ。
- 如权利要求41-45中任一项所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约18.45°、约 21.83°、约23.08°、约23.80°和约25.59°2θ。
- 如权利要求41-46中任一项所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约18.45°、约21.83°、约23.08°、约23.80°和约25.59°2θ。
- 如权利要求41-47中任一项所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱还具有三个或更多个选自下组的峰:约18.45°、约21.83°、约23.08°、约23.80°和约25.59°2θ。
- 如权利要求41-48中任一项所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱还具有所有选自下组的峰:约18.45°、约21.83°、约23.08°、约23.80°和约25.59°2θ。
- 如权利要求41-50中任一项所述的晶型D,其特征在于,所述晶型D的X-射线粉末衍射图谱如图7所示。
- 如权利要求41-52中任一项所述的晶型D,其特征在于,所述晶型D的差示扫描量热(DSC)图谱包括于约124.1℃处的吸热峰。
- 如权利要求41-53中任一项所述的晶型D,其特征在于,所述晶型D的差示扫描量热(DSC)图谱如图8所示。
- 如权利要求41-53中任一项所述的晶型D,其特征在于,在所述晶型D中二氯甲烷分子与所述化合物1的摩尔比为约0.8:1。
- 如权利要求55所述的晶型E,其特征在于,所述晶型E的X-射线粉末衍射图谱具有所有选自下组的峰:约9.10°、约13.49°和约18.24°2θ。
- 如权利要求55所述的晶型E,其特征在于,所述晶型E的X-射线粉末衍射图谱还具有一个或多个选自下组的峰:约13.03°、约20.13°、约22.63°、约23.35°、约25.06°、约27.51°和约29.46°2θ。
- 如权利要求55所述的晶型E,其特征在于,所述晶型E的X-射线粉末衍射图谱还具有两个或更多个选自下组的峰:约13.03°、约20.13°、约22.63°、约23.35°、约25.06°、约27.51°和约29.46°2θ。
- 如权利要求55所述的晶型E,其特征在于,所述晶型E的X-射线粉末衍射图谱还具有三个或更多个选自下组的峰:约13.03°、约20.13°、约22.63°、约23.35°、约25.06°、约27.51°和约29.46°2θ。
- 如权利要求55所述的晶型E,其特征在于,所述晶型E的X-射线粉末衍射图谱还具有所有选自下组的峰:约13.03°、约20.13°、约22.63°、约23.35°、约25.06°、约27.51°和约29.46°2θ。
- 如权利要求55-62中任一项所述的晶型E,其特征在于,所述晶型E的X-射线粉末衍射图谱如图9所示。
- 如权利要求55-62中任一项所述的晶型E,其特征在于,所述晶型E的差示扫描量热(DSC)图谱包括于约123.6℃和约269.0℃处的吸热峰。
- 如权利要求55-63中任一项所述的晶型E,其特征在于,所述晶型E的差示扫描量热(DSC)图谱如图10所示。
- 如权利要求55-64中任一项所述的晶型E,其特征在于,在所述晶型E中异丙醇分子与所述化合物1的摩尔比为约1:1。
- 如权利要求1-65中任一项所述的晶型,其特征在于,所述晶型是基本上纯的晶型,其中所述基本上纯是指具有大于90wt%的纯度。
- 一种药物组合物,其包含式(I)所示的化合物1和药学上可接受的载体,所述化合物1具有选自如下的晶型:如权利要求1-14中任一项所述的晶型A、如权利要求15-25中任一项所述的晶型B、如权利要求26-40中任一项所述的晶型C、如权利要求41-54中任一项所述的晶型D以及如权利要求55-65中任一项所述的晶型E。
- 如权利要求67所述的药物组合物,其中至少约85%、至少约90%、至少约95%、至少约99%、至少约99.5%、至少约99.9%或至少约99.99%的化合物1具有晶型A。
- 如权利要求67所述的药物组合物,其中至少约85%、至少约90%、至少约95%、至少约99%、至少约99.5%、至少约99.9%或至少约99.99%的化合物1具有晶型B。
- 如权利要求67所述的药物组合物,其中至少约85%、至少约90%、至少约95%、至少约99%、至少约99.5%、至少约99.9%或至少约99.99%的 化合物1具有晶型C。
- 如权利要求67所述的药物组合物,其中至少约85%、至少约90%、至少约95%、至少约99%、至少约99.5%、至少约99.9%或至少约99.99%的化合物1具有晶型D。
- 如权利要求67所述的药物组合物,其中至少约85%、至少约90%、至少约95%、至少约99%、至少约99.5%、至少约99.9%或至少约99.99%的化合物1具有晶型E。
- 如权利要求67所述的药物组合物,其进一步包括其他治疗剂。
- 一种药物组合物的制备方法,其包括将如权利要求1-66中任一项所述的晶型和药学上可接受的载体进行混合。
- 如权利要求1-66中任一项所述的晶型或如权利要求67-73中任一项所述的药物组合物在以下中的用途:(a)制备预防或治疗与SHP2活性/水平异常相关的疾病或病症的药物;(b)制备预防或治疗SHP2-介导的疾病或病症的药物;(c)制备抑制SHP2活性/水平的抑制剂药物;(d)体外非治疗性地抑制SHP2活性/水平;(e)体外非治疗性地抑制肿瘤细胞增殖;或(f)治疗与SHP2活性/水平异常相关的疾病或病症。
- 根据权利要求75所述的用途,其中,所述与SHP2活性/水平异常相关的疾病或病症或者SHP2-介导的疾病或病症为癌症,所述癌症选自下组:努南综合征、豹皮综合征、青少年髓单核细胞白血病、成神经细胞瘤、黑色素瘤、急性髓性白血病、乳腺癌、食道癌、肺癌、结肠癌、头癌、头颈的鳞状细胞癌、胃癌、间变性大细胞淋巴瘤、成胶质细胞瘤、肝细胞癌(HCC)、急性淋巴细胞白血病、肾上腺皮质癌、肛门癌、阑尾癌、星形细胞瘤、非典型类畸形/类瘤、基底细胞癌、胆管癌、膀胱癌、骨癌(骨肉瘤和恶性纤 维组织细胞瘤)、脑干神经胶质瘤、脑肿瘤、脑和脊髓肿瘤、支气管肿瘤、伯基特(Burkitt)淋巴瘤、子宫颈癌、慢性淋巴细胞性白血病、慢性粒细胞性白血病、结肠直肠癌、颅咽管瘤、胚胎肿瘤、子宫内膜癌、上皮细胞瘤、室管膜瘤、尤因肉瘤家族肿瘤、眼癌、视网膜母细胞瘤、胆囊癌、胃肠道类癌、胃肠道间质瘤(GIST)、胃肠道间质细胞瘤、生殖细胞瘤、神经胶质瘤、毛细胞白血病、头颈癌、霍奇金淋巴瘤、下咽癌、胰岛细胞瘤(内分泌胰腺)、卡波济肉瘤、肾癌、朗格汉斯细胞组织细胞增生症、喉癌、白血病、毛细胞白血病、肝癌、非小细胞肺癌、小细胞肺癌、淋巴瘤、髓母细胞瘤、髓上皮瘤、间皮瘤、口腔癌、多发性骨髓瘤、鼻咽癌、神经母细胞瘤、非霍奇金淋巴瘤、口咽癌、骨肉瘤、恶性骨纤维组织细胞瘤、卵巢癌、卵巢上皮癌、卵巢生殖细胞瘤、卵巢低恶性潜能肿瘤、胰腺癌、乳头状瘤病、甲状旁腺癌、阴茎癌、咽癌、松果体中间分化肿瘤、成骨细胞瘤和幕上原始神经外胚层肿瘤、垂体瘤、浆细胞肿瘤/多发性骨髓瘤、胸膜肺母细胞瘤、原发性中枢神经系统淋巴瘤、前列腺癌、直肠癌、肾细胞(肾)癌、视网膜母细胞瘤、横纹肌肉瘤、唾液腺癌、肉瘤、尤因肉瘤家族肿瘤、肉瘤、卡波西氏病、Sezary综合征、皮肤癌、小肠癌、软组织肉瘤、鳞状细胞癌、幕上原始神经外胚层肿瘤、T细胞淋巴瘤、睾丸癌、喉癌、胸腺瘤和胸腺癌、甲状腺癌、尿道癌、子宫癌、子宫肉瘤、阴道癌、外阴癌、Waldenstrom巨球蛋白血症和Wilms肿瘤。
- 一种抑制SHP2活性的方法,其包括以下步骤:对有此需要的受试者施用有效量的如权利要求1-66中任一项所述的晶型,或对有此需要的受试者施用有效量的如权利要求67-73中任一项所述的药物组合物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022577746A JP2023532217A (ja) | 2020-06-18 | 2021-06-17 | Shp2阻害剤の結晶形、その組成物、その製造方法及び応用 |
KR1020237002092A KR20230026458A (ko) | 2020-06-18 | 2021-06-17 | Shp2 억제제의 결정형 및 이의 조성물, 제조 방법과 용도 |
EP21826764.9A EP4169920A4 (en) | 2020-06-18 | 2021-06-17 | CRYSTALLINE FORM OF A SHP2 INHIBITOR AND COMPOSITION THEREOF, METHOD OF PREPARING THE SAME AND USE THEREOF |
CA3183063A CA3183063A1 (en) | 2020-06-18 | 2021-06-17 | Crystalline form of shp2 inhibitor, and composition thereof, preparation method therefor, and use thereof |
CN202180043362.7A CN115698007A (zh) | 2020-06-18 | 2021-06-17 | 一种shp2抑制剂的晶型及其组合物、制备方法和用途 |
US18/002,196 US20230339975A1 (en) | 2020-06-18 | 2021-06-17 | Crystalline form of shp2 inhibitor, and composition thereof, preparation method therefor, and use thereof |
AU2021290733A AU2021290733A1 (en) | 2020-06-18 | 2021-06-17 | Crystalline form of SHP2 inhibitor, and composition thereof, preparation method therefor, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020096778 | 2020-06-18 | ||
CNPCT/CN2020/096778 | 2020-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021254449A1 true WO2021254449A1 (zh) | 2021-12-23 |
Family
ID=79268476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/100673 WO2021254449A1 (zh) | 2020-06-18 | 2021-06-17 | 一种shp2抑制剂的晶型及其组合物、制备方法和用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230339975A1 (zh) |
EP (1) | EP4169920A4 (zh) |
JP (1) | JP2023532217A (zh) |
KR (1) | KR20230026458A (zh) |
CN (1) | CN115698007A (zh) |
AU (1) | AU2021290733A1 (zh) |
CA (1) | CA3183063A1 (zh) |
WO (1) | WO2021254449A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
WO2020094018A1 (zh) | 2018-11-06 | 2020-05-14 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
CN111153901A (zh) * | 2018-11-07 | 2020-05-15 | 如东凌达生物医药科技有限公司 | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 |
WO2020108590A1 (zh) * | 2018-11-30 | 2020-06-04 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
WO2020259679A1 (zh) * | 2019-06-28 | 2020-12-30 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
-
2021
- 2021-06-17 EP EP21826764.9A patent/EP4169920A4/en active Pending
- 2021-06-17 JP JP2022577746A patent/JP2023532217A/ja active Pending
- 2021-06-17 US US18/002,196 patent/US20230339975A1/en active Pending
- 2021-06-17 CA CA3183063A patent/CA3183063A1/en active Pending
- 2021-06-17 WO PCT/CN2021/100673 patent/WO2021254449A1/zh unknown
- 2021-06-17 AU AU2021290733A patent/AU2021290733A1/en active Pending
- 2021-06-17 KR KR1020237002092A patent/KR20230026458A/ko active Search and Examination
- 2021-06-17 CN CN202180043362.7A patent/CN115698007A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
WO2020094018A1 (zh) | 2018-11-06 | 2020-05-14 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
CN111153901A (zh) * | 2018-11-07 | 2020-05-15 | 如东凌达生物医药科技有限公司 | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 |
WO2020108590A1 (zh) * | 2018-11-30 | 2020-06-04 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
WO2020259679A1 (zh) * | 2019-06-28 | 2020-12-30 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
Non-Patent Citations (2)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2005 |
"Remingtons Pharmaceutical Sciences", 1991, MACK PUB. CO. |
Also Published As
Publication number | Publication date |
---|---|
JP2023532217A (ja) | 2023-07-27 |
AU2021290733A1 (en) | 2023-02-23 |
KR20230026458A (ko) | 2023-02-24 |
EP4169920A1 (en) | 2023-04-26 |
US20230339975A1 (en) | 2023-10-26 |
CA3183063A1 (en) | 2021-12-23 |
CN115698007A (zh) | 2023-02-03 |
EP4169920A4 (en) | 2024-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6317320B2 (ja) | 上皮成長因子受容体キナーゼ阻害剤の塩 | |
JP6457658B2 (ja) | 安定した、溶媒和物が含まれないアプレミラスト結晶形ii、及びその製造方法 | |
BR112014022789B1 (pt) | Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo | |
JP2015017116A (ja) | 癌および他の疾患または障害の処置のための、4−[6−メトキシ−7−(3−ピペリジン−1−イル−プロポキシ)キナゾリン−4−イル]ピペラジン−1−カルボン酸(4−イソプロポキシフェニル)−アミドの乳酸塩およびその薬学的組成物 | |
WO2017152707A1 (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
WO2018184185A1 (zh) | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 | |
JP2015180679A (ja) | ナトリウム4−{[9−クロロ−7−(2−フルオロ−6−メトキシフェニル)−5H−ピリミド[5,4−d][2]ベンゾアゼピン−2−イル]アミノ}−2−メトキシベンゾエートの結晶形 | |
WO2016124067A1 (zh) | 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法 | |
JP2023157909A (ja) | 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態 | |
CN115385894A (zh) | 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法 | |
US20230374030A1 (en) | Solid-state forms of relugolix | |
WO2018082687A1 (zh) | 一种GnRH受体拮抗剂的多晶型及其制备方法 | |
US20190100519A1 (en) | Hydrochloride salt crystal of drug for treating or preventing jak-associated disease and preparation method thereof | |
WO2021254449A1 (zh) | 一种shp2抑制剂的晶型及其组合物、制备方法和用途 | |
EP3315493B1 (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
EP3941472A1 (en) | <smallcaps/>? ? ?n? ? ? ? ?crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof | |
WO2022099442A1 (zh) | 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备 | |
WO2022194160A1 (zh) | 非索替尼固体形式及其制备方法 | |
WO2024120441A1 (zh) | 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式 | |
RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
RU2792620C2 (ru) | Кристаллическая форма ингибитора parp-1 и способ ее получения | |
WO2017152846A1 (zh) | 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法 | |
TW202421127A (zh) | 5H-吡咯并〔2,3-d〕嘧啶-6(7H)-酮及其鹽體之結晶 | |
WO2020222190A1 (en) | Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide | |
CN115515954A (zh) | 6-氯-7-(4-(4-氯苄基)哌嗪-1-基)-2-(1,3-二甲基-1h-吡唑-4-基)-3h-咪唑并[4,5-b]吡啶的盐和多晶型形式 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21826764 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3183063 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022577746 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237002092 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021826764 Country of ref document: EP Effective date: 20230118 |
|
ENP | Entry into the national phase |
Ref document number: 2021290733 Country of ref document: AU Date of ref document: 20210617 Kind code of ref document: A |